

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |  |   |   |
|---|--|---|---|
| (51) International Patent Classification 6 :<br><b>C12N 15/18, C07K 14/475, C12N 5/10,<br/>G01N 33/68, 33/53, A61K 38/18</b>  |  | A1  | (11) International Publication Number: <b>WO 99/05278</b> |
| (21) International Application Number: <b>PCT/US98/09801</b>  |  | (43) International Publication Date: <b>4 February 1999 (04.02.99)</b>  |   |
| (22) International Filing Date: <b>23 July 1998 (23.07.98)</b>  |  | <b>(81) Designated States:</b> AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).<br><br><b>Published</b><br><i>With international search report.<br/>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |   |
| (30) Priority Data:<br><b>60/053,549                      23 July 1997 (23.07.97)                      US</b>   |  |   |   |
| (71) Applicant: <b>BRIGHAM &amp; WOMEN'S HOSPITAL, INC.</b><br><b>[US/US]; 75 Francis Street, Boston, MA 02115 (US).</b>  |  |   |   |
| (72) Inventors: <b>SHINOHARA, Toshimichi; 35 Shaw Road, Chestnut Hill, MA 02167 (US). SINGH, Dhirenda; 254 Cypress Street, Brookline, MA 02146 (US). CHYLACK, Leo, T., Jr.; 15 Bradford Road, Duxbury, MA 02331 (US).</b> |  |   |   |
| (74) Agent: <b>GATES, Edward, R.; Wolf, Greenfield &amp; Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).</b>   |  |   |   |

(54) Title: **LENS EPITHELIAL CELL DERIVED GROWTH FACTOR**



(57) Abstract

The invention pertains to nucleic acids encoding a lens epithelial cell derived growth factor protein, including fragments and biologically functional variants thereof. The invention also pertains to therapeutics and diagnostics involving the foregoing proteins and genes and agents that bind the foregoing proteins and genes.

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   |    |  | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | ML | Mali   | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MN | Mongolia                                     | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MR | Mauritania                                   | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MW | Malawi                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | MX | Mexico                                       | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NE | Niger  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NL | Netherlands                                  | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NO | Norway                                       | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | NZ | New Zealand                                  |    |                          |
| CM | Cameroon                 |    |  | PL | Poland                                       |    |                          |
| CN | China                    | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CU | Cuba                     | KZ | Kazakhstan                               | RO | Romania                                      |    |                          |
| CZ | Czech Republic           | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| DE | Germany                  | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DK | Denmark                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| EE | Estonia                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |

## LENS EPITHELIAL CELL DERIVED GROWTH FACTOR

### Field of the Invention

This invention relates to nucleic acids and encoded polypeptides of a lens epithelial cell derived growth factor (LEDGF), and diagnostics and therapeutics related to medical conditions associated with such genes and polypeptides, including cataracts.

### Background of the Invention

The term cataract is used to define the opacification of the normally clear and transparent crystalline lens. Several types of cataract etiology have been described. For example, *congenital* cataracts occur as a complication of intrauterine rubella, herpes simplex, herpes zoster, syphilis and cytomegalic inclusion disease, the majority being idiopathic or inherited. *Acquired* cataracts result from trauma, radiation, drugs, metabolic disorders, ocular inflammatory disorders, or aging (senile or age-related cataracts). It has been estimated that nearly one billion elderly people throughout the world have age-related cataracts [ARCs] (Thylefors et al., *Available Data on Blindness*, Geneva, Switzerland; WHO Program for the Prevention of Blindness, 1994). The underlying mechanisms responsible for ARCs, however, are not well understood.

Although the anterior lens is covered with a single layer of cuboidal lens epithelial cells (LECs), most of the remaining lens is composed of anucleated fiber cells. With age, even though the lens enlarges, the epithelial cell density and cytological activity decline (Guggenmoos-Holzmann et al., *Invest. Ophthalmol. Vis. Sci.* 30:330-332, 1989, Konofsky et al., *Ophthalmology* 94:875-880, 1987, and Straatsma et al., *Am. J. Ophthalmol.* 112:283-296, 1991); this decrease is most pronounced in lenses with cortical and mixed cataracts. Also in these cataracts, there is greater LEC metaplasia than in the normal lens (Saitoh et al., *Nippon Ganka Gakkai Zasshi* 94:176-180, 1990, Streeten and Eshaghian, *Arch. Ophthalmol.* 96:1653-1658, 1978, and von Sallmann, *Am. J. Ophthalmol.* 44:159-170, 1957). Since the LECs maintain lens homeostasis, a decrease in epithelial cell number or metabolic activity is expected to disturb normal lens physiology.

For survival, the cells require growth or proliferation factors, and several such factors have been reported: neurotrophic factor for neurons (Cowan et al., *Science* 225:1258-1264, 1984, Purves, *Body and brain. A trophic theory of natural connections*. Harvard University

Press. Cambridge, MA. pp. 231, 1988, Barde, *Neuron* 2:1525-1534, 1989, and Oppenheim, *Science* 240:919-922, 1991), colony stimulation factor for myeloid cells (Metcalf, *Nature* 339:27-30, 1989, Williams et al., *Nature* 343:76-78, 1990, and Koury and Bondurant, *Science* 248:378-381, 1990), specific hormones for endocrine-dependent cells (Kerr and Searle, *Virchows. Arch. B. Cell Pathol.* 13:87-92, 1973, Krypaniou and Issacs, *Endocrinology* 122:552-562, 1988, and Wyllie et al., *J. Pathol.* 111:85-94, 1973), and specific growth factors for oligodendrocytes (Barres et al., *Cell* 70:31-46, 1992). Ishizaki et al. predicted that LECs must have such growth factors (*J. Cell Biol.* 121:899-908, 1993].

It was demonstrated recently (Ibaraki et al., *Exp. Eye Res.* 64:229-238, 1997 and Singh et al., *J. Immunol.* 155:993-999, 1995), that auto-antibodies against lens  $\beta$ -crystallins induced LEC damage and cataract formation in mice. Both serum and monoclonal antibody (Ab) transfer studies established that humoral rather than cellular immunity was responsible for the death of LECs. It was found that anti- $\beta$  crystallin antibodies (Abs) killed LECs and that damage was age-dependent (Singh et al., *J. Immunol.* 155:993-999, 1995). In human serum, anti-lens Abs were more prevalent in patients with age-related cataracts (98%) than in subjects with clear lenses (40%) (Singh et al., *Exp. Eye Res.* Submitted, 1997). It was also shown that more than 96% of the sera from patients with ARC, but fewer than 30% with clear lenses, were cytotoxic. Mixing cytotoxic anti-lens Abs with whole lens antigens (Ags) decreased or eliminated the cytotoxic effects. These findings raise the possibility that human ARCs are caused by an autoimmune insult to the LECs.

There exists a need to influence favorably the physical properties of the crystalline lens.

There also exists a need to identify the gene(s) responsible for cataract and age-related cataract in particular, and to provide therapy for preventing and treating cataracts.

An object of the invention is to provide compounds that desirably influence the physical properties of the crystalline lens.

Another object of the invention is to provide therapeutics for treating diseases or conditions involving LEDGF expression.

Still another object of the invention is to provide diagnostics and research tools relating to LEDGF. These and other objects will be described in greater detail below.

### Summary of the Invention

We describe herein the molecular cloning and characterization of LEDGF, a novel polypeptide that stimulates protein synthesis. This increase in protein synthesis leads to the enhanced growth of a variety of cell types such as those of epithelial, epidermal or kidney origin, including lens epithelial cells. Anti-LEDGF Abs blocked the stimulatory effects of this protein, resulting in the death of LECs and other types of cells, including neuronal, fibroblasts, etc. Increased levels of anti-LEDGF Abs were found in patients with ARCs, suggesting that neutralization of LEDGF by auto-Abs is responsible for the development of cataracts and ARCs in particular.

The invention provides isolated nucleic acid molecules, unique fragments of those molecules, expression vectors containing the foregoing, and host cells transfected with those molecules. The invention also provides isolated polypeptides and agents which bind such polypeptides, including antibodies. The foregoing can be used, *inter alia*, in the diagnosis or treatment of conditions characterized by the aberrant expression of a LEDGF nucleic acid or polypeptide. The invention also provides methods for identifying pharmacological agents useful in the diagnosis or treatment of such conditions. Here, we present the cDNA cloning of a 61 kDa protein, LEDGF, which stimulates proliferation of a number of different cell types, particularly those of epithelial character, and include lens epithelial cells.

According to one aspect of the invention, isolated nucleic acid molecules that code for a lens epithelial cell derived growth factor polypeptide are provided and include: (a) nucleic acid molecules which hybridize under stringent conditions to a molecule consisting of a nucleic acid of SEQ ID NO:1 and which code for a lens epithelial cell derived growth factor polypeptide, (b) deletions, additions and substitutions of (a) which code for a respective lens epithelial cell derived growth factor polypeptide, (c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and (d) complements of (a), (b) or (c). In certain embodiments, the isolated nucleic acid molecule comprises nucleotides 1-3360 of SEQ ID NO:1. In some embodiments the isolated nucleic acid molecules are those comprising the human cDNA or gene corresponding to SEQ ID NO:13. The isolated nucleic acid molecule also can comprise a molecule which encodes the polypeptide of SEQ ID NO:2.

The invention in another aspect is an isolated nucleic acid molecule selected from the group consisting of (a) a fragment of a nucleic acid molecule of SEQ ID NO:1, of sufficient

length to represent a sequence unique within the human genome, and identifying a nucleic acid encoding a Lens Epithelial Cell Derived Growth Factor polypeptide, (b) complements of (a), provided that the fragment includes a sequence of contiguous nucleotides which is not identical to any sequence selected from the sequence group consisting of (1) sequences having the GenBank accession numbers of Table III, (2) complements of (1), and (3) fragments of (1) and (2).

In one embodiment the sequence of contiguous nucleotides is selected from the group consisting of (1) at least two contiguous nucleotides nonidentical to the sequence group, (2) at least three contiguous nucleotides nonidentical to the sequence group, (3) at least four contiguous nucleotides nonidentical to the sequence group, (4) at least five contiguous nucleotides nonidentical to the sequence group, (5) at least six contiguous nucleotides nonidentical to the sequence group, (6) at least seven contiguous nucleotides nonidentical to the sequence group.

In another embodiment the fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20 nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 40 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides, 200 nucleotides, 1000 nucleotides and every integer length therebetween.

In yet another embodiment the molecule encodes a polypeptide which, or a fragment of which, binds a human antibody.

According to another aspect, the invention involves expression vectors, and host cells transformed or transfected with such expression vectors, comprising the nucleic acid molecules described above.

According to another aspect of the invention, an isolated polypeptide is provided. The isolated polypeptide is encoded by the isolated nucleic acid molecule of claim 1, 2, or 3. In some embodiments, the isolated polypeptide is a secreted protein encoded by the nucleic acid of claim 2, comprising a polypeptide having the sequence of SEQ ID NO:2. In other embodiments, the isolated polypeptide comprises a fragment or variant of the foregoing of sufficient length to represent a sequence unique within the human genome and identifying a polypeptide that has protein synthesis induction activity, provided that the fragment includes a sequence of contiguous amino acids which is not identical to any sequence selected from the sequence group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID

NO:12, and SEQ ID NO:22. In another embodiment, immunogenic fragments of the polypeptide molecules described above are provided.

According to another aspect of the invention, isolated polypeptides are provided which selectively bind a polypeptide encoded by the nucleic acid of claim 1, 2, or 3. Preferably the isolated polypeptides selectively bind a polypeptide which comprises the sequence of SEQ ID NO:2, or fragments thereof (e.g. SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8). In preferred embodiments, the isolated binding polypeptides include antibodies and fragments of antibodies (e.g., Fab, F(ab)<sub>2</sub>, Fd and antibody fragments which include a CDR3 region which binds selectively to the LEDGF polypeptide). In certain embodiments the antibodies are human.

According to another aspect of the invention, a method is provided for determining an individual's susceptibility to developing cataracts. A test sample containing antibodies of the individual is obtained. Anti-LEDGF antibody levels are measured in the test sample and compared to a control. The individual's risk profile of developing a cataract is characterized based upon the level of the anti-LEDGF antibody in comparison to the control. The control may be a predetermined value such as serum titer of anti-LEDGF antibodies of OD<sub>492</sub> ≥ 200. In a preferred embodiment the test sample is blood, although the test sample can also be tissue such as epidermis and buccal scrapings.

The invention also contemplates kits comprising a package including assays for anti-LEDGF antibodies, LEDGF epitopes, LEDGF nucleic acids, and instructions, and optionally related materials such as controls, for example, a number, color chart, or an epitope of the expression product of the nucleic acid of claim 1 for comparing the level of anti-LEDGF antibodies in the test sample as determined by the assay with a control value or control assay results to determine a risk of developing a cataract. The kits may also include an assay for anti-β-crystallin antibodies.

According to another aspect of the invention, a method is provided for treating subjects with an abnormally elevated level of anti-LEDGF antibodies to inhibit the development of cataracts. The method involves administering to an individual in need of such treatment a polypeptide encoded by the isolated nucleic acid molecule of claim 1, 2 or 3 having protein synthesis induction activity in an amount effective to inhibit the formation of opacities in the crystalline lens. In preferred embodiments of the invention, LEDGF polypeptides are administered orally or conjugated to antibodies and administered *intra*

venously in an amount effective to tolerize the subject to LEDGF and to lower the risk of the subject developing a cataract. Nasal administration is also particularly contemplated.

Another aspect of the invention is a method for determining the level of LEDGF expression in a subject. Expression is defined either as LEDGF mRNA expression or LEDGF polypeptide expression. Preferred embodiments of the invention include PCR and Northern blotting for measuring mRNA expression, and monoclonal or polyclonal LEDGF antisera as part of the reagents to measure LEDGF polypeptide expression. Also in certain embodiments, tissue samples such as biopsy samples, and biological fluids such as blood, are used as the source of test samples. LEDGF expression is compared to a measured control.

The invention in a further aspect involves a method for decreasing LEDGF mediated activity in a subject. An agent that selectively binds to an isolated nucleic acid molecule of the invention or an expression product thereof is administered to a subject in need of such treatment, in an amount effective to decrease LEDGF mediated activity in the subject. Preferred agents are antisense nucleic acids, including modified nucleic acids, and polypeptides such as antibodies against LEDGF.

The invention in another aspect involves a method for decreasing LEDGF mediated activity in a subject with a cancer that expresses LEDGF. An agent that selectively binds to an isolated nucleic acid molecule of the invention or an expression product thereof is administered to a subject in need of such treatment, in an amount effective to decrease LEDGF mediated activity in the subject in order to inhibit or slow down the proliferation of cancer. Preferred agents are antisense nucleic acids, including modified nucleic acids, and polypeptides such as antibodies against LEDGF.

According to another aspect of the invention, methods for inducing cell-death are also provided. The methods involve contacting a cell with an amount of an inhibitor of LEDGF effective to inhibit LEDGF mediated activity in the cell, and induce cell-death. In certain embodiments, the inhibitor is an antisense nucleic acid which inhibits the expression of LEDGF, or a polypeptide that binds to LEDGF and blocks its activity.

According to still another aspect of the invention, methods for inhibiting a cell's differentiation both *in vivo* and *in vitro* are also provided. The methods involve contacting a mammalian cell with an amount of a LEDGF inhibitor effective to decrease LEDGF mediated activity in the mammalian cell and prevent it from differentiating. In certain embodiments, the inhibitor is an antisense nucleic acid which inhibits the expression of



LEDGF, or a polypeptide that binds to LEDGF and blocks its activity.

Another aspect of the invention is a method for increasing cell proliferation. A cell expressing a LEDGF receptor is contacted with an agent that increases LEDGF stimulated cell proliferation in an amount effective to stimulate such proliferation. The agent can be a polypeptide encoded by the nucleic acid of SEQ ID NO:1. The agent can also be a polypeptide having the amino acid sequence of SEQ ID NO:2, or an LEDGF receptor stimulatory fragment thereof.

Another aspect of the invention involves a method for inducing wound healing in a subject. An agent as described in the immediately preceding paragraph is administered to a subject in need of such treatment, in an amount effective to increase LEDGF mediated activity in the subject in order to promote the proliferation of cells such as epidermal cells and accelerate wound healing.

According to still another aspect of the invention, methods for inhibiting environmental stress-induced cell-death both *in vivo* and *in vitro* are also provided. The methods involve contacting a mammalian cell expressing a LEDGF receptor, and under environmental stress otherwise sufficient to induce cell-death, with an agent that increases LEDGF mediated activity in an amount effective to inhibit death of the mammalian cell which otherwise would result from such environmental stress. The agent can be a polypeptide encoded by the nucleic acid of SEQ ID NO:1. The agent can also be a polypeptide having the amino acid sequence of SEQ ID NO:2, or an LEDGF receptor stimulatory fragment thereof. The methods of the invention are preferably used when increased temperatures, physical trauma, oxidative, osmotic or chemical stress, and UV irradiation form part of the environmental stress.

According to still another aspect of the invention, methods for increasing heat-shock protein activity in a cell, both *in vivo* and *in vitro* are provided. The methods involve contacting the cell with an isolated nucleic acid molecule of claim 1 or an expression product thereof, in an amount effective to increase LEDGF mediated activity in the cell and to increase heat-shock protein activity in the cell. The agent can be a polypeptide encoded by the nucleic acid of SEQ ID NO:1. The agent can also be a polypeptide having the amino acid sequence of SEQ ID NO:2, or an LEDGF receptor stimulatory fragment thereof.

The invention in another aspect provides compositions comprising an antisense nucleic acid which selectively binds to the nucleic acid of claim 1 and which reduces the

expression of LEDGF, and a pharmaceutically acceptable carrier.

The present invention thus involves, in several aspects, LEDGF polypeptides, genes encoding those polypeptides, functional modifications and variants of the foregoing, useful fragments of the foregoing, as well as therapeutics and diagnostics relating thereto.

5        These and other objects of the invention will be described in further detail in connection with the detailed description of the invention.

### **Brief Description of the Drawings**

10        Figure 1 shows the *in vitro* effects of over-expressing LEDGF in LECs. Fig. 1A shows the over-expression of LEDGF in LECs as compared to a negative control (vector alone). Fig. 1B shows that LEDGF is present (secreted) in the culture medium.

Figure 2 shows the growth stimulating effects of LEDGF-conditioned medium on LECs.

15        Figure 3 shows the *in vitro* anti-LEDGF Ab effects on LECs. Fig. 3A shows the inhibition of <sup>3</sup>H-thymidine uptake in mouse LECs by adding anti-LEDGF Abs to the medium. Fig. 3B shows the effect of anti-LEDGF Abs on the survival of human LECs.

Figure 4 shows the presence of anti-LEDGF Abs in patients with cataracts.

20        Figure 5 depicts a kit comprising an agent of the invention (e.g., anti-LEDGF Abs, LEDGF epitopes, etc.), a control agent, and instructions for utilizing such agents in diagnostic or therapeutic applications.

### **Brief Description of the Sequences**

SEQ ID NO:1 is the nucleotide sequence of the human LEDGF cDNA.

25        SEQ ID NO:2 is the predicted amino acid sequence of the translation product of human LEDGF cDNA.

SEQ ID NO:3 is a unique nucleotide sequence of the 5'-end of the human LEDGF cDNA.

SEQ ID NO:4 is the predicted amino acid sequence encoded by SEQ ID NO:3.

30        SEQ ID NO:5 is a unique nucleotide sequence of the 3'-end of the human LEDGF cDNA.

SEQ ID NO:6 is the predicted amino acid sequence encoded by SEQ ID NO:5.

SEQ ID NO:7 is the nucleotide sequence of the human LEDGF cDNA that excludes a

large portion of the 5'-end of the human LEDGF cDNA.

SEQ ID NO:8 is the predicted amino acid sequence encoded by SEQ ID NO:7 that maintains native LEDGF stimulating activity.

5 SEQ ID NO:9 is a contiguous sequence of 13 amino acids common to both LEDGF and HDGF.

SEQ ID NO:10 is a contiguous sequence of 15 amino acids common to both LEDGF and HDGF.

SEQ ID NO:11 is a contiguous sequence of 9 amino acids common to both LEDGF and HDGF.

10 SEQ ID NO:12 is a contiguous sequence of 6 amino acids common to both LEDGF and HDGF.

SEQ ID NO:13 is the nucleotide sequence of the largest open reading frame of the human LEDGF cDNA of SEQ ID NO:1 encoding for the polypeptide of SEQ ID NO:2.

SEQ ID NO:14 is the amino acid sequence of the human HDGF.

15 SEQ ID NO:15 is the amino acid sequence of the mouse HDGF.

SEQ ID NO:16 is the amino acid sequence of the transcription factor LFB1/HNF1.

SEQ ID NO:17 is the nucleotide sequence of the 5' noncoding-end of SEQ ID NO:1.

SEQ ID NO:18 is the nucleotide sequence of the 3' noncoding-end of SEQ ID NO:1.

SEQ ID NO:19 is a primer spanning the 5' noncoding-coding region of SEQ ID NO:1.

20 SEQ ID NO:20 is a primer from the 3' noncoding region of SEQ ID NO:1.

SEQ ID NO:21 is the partial nucleotide sequence of human autoantigen DFS70, GenBank Acc. No. U94319.

SEQ ID NO:22 is the predicted amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:21.

25

### **Detailed Description of the Invention**

One aspect of the invention involves the cloning of a cDNA encoding a Lens Epithelial Cell Derived Growth Factor (LEDGF). A lens epithelial cell derived growth factor according to the invention is an isolated nucleic acid molecule that comprises a nucleic acid molecule of SEQ ID NO:1, and codes for a protein that induces protein synthesis in an epithelial cell. A preferred factor of the invention includes additional features. For example, it induces growth of epithelial cells, and most preferably kidney, epidermal, retinal and

30

neuronal cells too. It is a secreted protein with a molecular mass of 61 kDa, and it is necessary for survival of epithelial cells expressing it. By necessary for survival it is meant that interfering with the activity of the factor in a cell expressing the factor, such as a lens epithelial cell, results in cell-death. The sequence of the human gene is presented as SEQ ID NO:1, and the predicted amino acid sequence of this gene's protein product is presented as SEQ ID NO:2.

As used herein, a subject is a human, non-human primate, cow, horse, pig, sheep, goat, dog, cat or rodent. In all embodiments human LEDGF and human subjects are preferred.

Analysis of the sequence by comparison to nucleic acid and protein databases show that LEDGF shares a limited, localized homology (35% at the nucleotide level, 20% at the amino acid level) to the hepatoma-derived growth factor (HDGF - SEQ ID NOs:14 and 15) (Nakamura et al., *J. Biol. Chem.* 269:25143-25149, 1994). Limited homology is also shared between LEDGF and the liver specific transcriptional factor LFB1/HFN1 (SEQ ID NO:16) (Bartkowski et al., *Mol. Cell. Biol.* 13: 421-431, 1993). Extended homology is shared with the nucleic acid of SEQ ID NO:21. This molecule represents the partial nucleotide sequence of human autoantigen DFS70, GenBank Acc. No. U94319. Its 5'-end, however, is missing and no known function has been assigned to this molecule.

The invention thus involves in one aspect a lens epithelial cell derived growth factor polypeptide, the gene encoding this polypeptide, functional modifications and variants of the foregoing, useful fragments of the foregoing, as well as diagnostics and therapeutics relating thereto.

As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is

isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art.

As used herein with respect to polypeptides, the term "isolated" means separated from its native environment in sufficiently pure form so that it can be manipulated or used for any one of the purposes of the invention. Thus, isolated means sufficiently pure to be used (i) to  
5 raise and/or isolate antibodies, (ii) as a reagent in an assay, or (iii) for sequencing, etc.

According to the invention, isolated nucleic acid molecules that code for a lens epithelial cell derived growth factor polypeptide include: (a) nucleic acid molecules which hybridize under stringent conditions to a molecule consisting of a nucleic acid of SEQ ID  
10 NO:1 and which code for a lens epithelial cell derived growth factor polypeptide, (b) deletions, additions and substitutions of (a) which code for a respective lens epithelial cell derived growth factor polypeptide, (c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and (d) complements of (a), (b) or (c).

Homologs and alleles of the LEDGF nucleic acids of the invention can be identified  
15 by conventional techniques. Thus, an aspect of the invention is those nucleic acid sequences which code for LEDGF polypeptides and which hybridize to a nucleic acid molecule consisting of the coding region of SEQ ID NO:1, under stringent conditions. The term "stringent conditions" as used herein refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references which compile such  
20 methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. More specifically, stringent conditions, as used herein, refers, for example, to  
25 hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM NaH<sub>2</sub>PO<sub>4</sub>(pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetracetic acid. After hybridization, the membrane upon which the DNA is transferred is washed at 2 x SSC at room temperature and then at 0.1  
30 x SSC/0.1 x SDS at temperatures up to 68°C.

There are other conditions, reagents, and so forth which can be used, and would result in a similar degree of stringency. The skilled artisan will be familiar with such conditions,

and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of homologs and alleles of LEDGF nucleic acids of the invention. The skilled artisan also is familiar with the methodology for screening cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

In general homologs and alleles typically will share at least 40% nucleotide identity and/or at least 50% amino acid identity to SEQ ID NO:1 and SEQ ID NO:2, respectively, in some instances will share at least 50% nucleotide identity and/or at least 65% amino acid identity and in still other instances will share at least 60% nucleotide identity and/or at least 75% amino acid identity. The homology can be calculated using various, publicly available software tools developed by NCBI (Bethesda, Maryland) that can be obtained through the internet (<ftp://ncbi.nlm.nih.gov/pub/>). Exemplary tools include the BLAST system available at <http://www.ncbi.nlm.nih.gov>. Pairwise and ClustalW alignments (BLOSUM30 matrix setting) as well as Kyte-Doolittle hydropathic analysis can be obtained using the MacVector sequence analysis software (Oxford Molecular Group). Watson-Crick complements of the foregoing nucleic acids also are embraced by the invention.

In screening for LEDGF related genes, such as homologs and alleles of LEDGF, a Southern blot may be performed using the foregoing conditions, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film or a phosphorimager plate to detect the radioactive signal.

Given that the expression of the LEDGF gene is abundant in certain human tissues, and given the teachings herein of a full-length human LEDGF cDNA clone, other mammalian sequences such as the mouse cDNA clone corresponding to the human LEDGF gene can be isolated from a cDNA library prepared from one or more of the tissues in which LEDGF expression is abundant, using standard colony hybridization techniques.

The invention also includes degenerate nucleic acids which include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT and AGC. Each of the six codons is equivalent for the purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the art that any of the serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a serine residue into an elongating

LEDGF polypeptide. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to: CCA, CCC, CCG and CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons).  
5 Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of the genetic code.

The invention also provides isolated unique fragments of SEQ ID NO:1 or SEQ ID NO:13 or complements thereof. A unique fragment is one that is a 'signature' for the larger  
10 nucleic acid. For example, the unique fragment is long enough to assure that its precise sequence is not found in molecules within the human genome outside of the LEDGF nucleic acids defined above (and human alleles). Those of ordinary skill in the art may apply no more than routine procedures to determine if a fragment is unique within the human genome. Unique fragments, however, exclude fragments completely composed of the nucleotide  
15 sequences of any of GenBank accession numbers listed in Table III or other previously published sequences as of the filing date of the priority document for sequences listed in the priority document.

A fragment which is completely composed of the sequence described in the foregoing GenBank deposits is one which does not include any of the nucleotides unique to the  
20 sequences of the invention. Thus, a unique fragment must contain a nucleotide sequence other than the exact sequence of those in GenBank or fragments thereof. The difference may be an addition, deletion or substitution with respect to the GenBank sequence or it may be a sequence wholly separate from the GenBank sequence.

Unique fragments can be used as probes in Southern and Northern blot assays to  
25 identify such nucleic acids, or can be used in amplification assays such as those employing PCR. As known to those skilled in the art, large probes such as 200, 250, 300 or more nucleotides are preferred for certain uses such as Southern and Northern blots, while smaller fragments will be preferred for uses such as PCR. Unique fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide  
30 fragments, as demonstrated in the Examples, or for generating immunoassay components. Likewise, unique fragments can be employed to produce nonfused fragments of the LEDGF polypeptides, useful, for example, in the preparation of antibodies, immunoassays or

therapeutic applications. Unique fragments further can be used as antisense molecules to inhibit the expression of LEDGF nucleic acids and polypeptides, particularly for therapeutic purposes as described in greater detail below.

As will be recognized by those skilled in the art, the size of the unique fragment will depend upon its conservancy in the genetic code. Thus, some regions of SEQ ID NO:1 or  
5 SEQ ID NO:13 and complements will require longer segments to be unique while others will require only short segments, typically between 12 and 32 nucleotides long (e.g. 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and 32 bases) or more, up to the entire length of the disclosed sequence. As mentioned above, this disclosure intends to  
10 embrace each and every fragment of each sequence, beginning at the first nucleotide, the second nucleotide and so on, up to 8 nucleotides short of the end, and ending anywhere from nucleotide number 8, 9, 10 and so on for each sequence, up to the very last nucleotide, (provided the sequence is unique as described above). Virtually any segment of the region of  
15 SEQ ID NO:1 beginning at nucleotide 1 and ending at nucleotide 3360, or SEQ ID NO:13 beginning at nucleotide 1 and ending at nucleotide 1593, or complements thereof, that is 18 or more nucleotides in length will be unique. Those skilled in the art are well versed in methods for selecting such sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from other sequences in the human genome of the fragment to those on known databases typically is all that is necessary, although *in vitro*  
20 confirmatory hybridization and sequencing analysis may be performed.

As mentioned above, the invention embraces antisense oligonucleotides that selectively bind to a nucleic acid molecule encoding a LEDGF polypeptide, to decrease LEDGF activity. This is desirable in virtually any medical condition wherein a reduction of LEDGF activity is desirable, including certain cancers. Antisense LEDGF molecules, in this  
25 manner, can be used to slow down or arrest the proliferation of cancer cells *in vivo*. When using antisense preparations of the invention, slow intravenous administration is preferred.

As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under  
30 physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or



translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon SEQ ID NO:1 or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides (Wagner et al., *Nat. Med.* 1(11):1116-1118, 1995). Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted by antisense oligonucleotides. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.* 14(5):439-457, 1994) and at which proteins are not expected to bind. Finally, although, SEQ ID No:1 discloses a cDNA sequence, one of ordinary skill in the art may easily derive the genomic DNA corresponding to this sequence. Thus, the present invention also provides for antisense oligonucleotides which are complementary to the genomic DNA corresponding to SEQ ID NO:1. Similarly, antisense to allelic or homologous LEDGF cDNAs and genomic DNAs are enabled without undue experimentation.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be

covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

5 In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

10 The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, 15 phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamidates, carboxymethyl esters and peptides.

20 The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and 25 hybridizable with, under physiological conditions, nucleic acids encoding LEDGF polypeptides, together with pharmaceutically acceptable carriers. Antisense oligonucleotides may be administered as part of a pharmaceutical composition. Such a pharmaceutical composition may include the antisense oligonucleotides in combination with any standard physiologically and/or pharmaceutically acceptable carriers which are known in the art. The compositions should be sterile and contain a therapeutically effective amount of the antisense 30 oligonucleotides in a unit of weight or volume suitable for administration to a patient. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with

the effectiveness of the biological activity of the active ingredients. The term "physiologically acceptable" refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art.

The invention also involves expression vectors coding for LEDGF proteins and fragments and variants thereof and host cells containing those expression vectors. Virtually any cells, prokaryotic or eukaryotic, which can be transformed with heterologous DNA or RNA and which can be grown or maintained in culture, may be used in the practice of the invention. Examples include bacterial cells such as *E. coli* and mammalian cells such as mouse, hamster, pig, goat, primate, etc. They may be of a wide variety of tissue types, including mast cells, fibroblasts, oocytes and lymphocytes, and they may be primary cells or cell lines. Specific examples include CHO cells and COS cells. Cell-free transcription systems also may be used in lieu of cells.

As used herein, a "vector" may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell. Vectors are typically composed of DNA although RNA vectors are also available. Vectors include, but are not limited to, plasmids, phagemids and virus genomes. A cloning vector is one which is able to replicate in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or

sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g.,  $\beta$ -galactosidase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein). Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.

As used herein, a coding sequence and regulatory sequences are said to be "operably" joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribed and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of

heterologous DNA (RNA) encoding LEDGF polypeptide or fragment or variant thereof. That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.

Preferred systems for mRNA expression in mammalian cells are those such as pRc/CMV (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen, Carlsbad, CA), which contains an Epstein Barr virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 $\alpha$ , which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (*Nuc. Acids Res.* 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (*Mol. Cell. Biol.* 16:4710-4716, 1996). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (*J. Clin. Invest.* 90:626-630, 1992). The use of the adenovirus as an Adeno.P1A recombinant is disclosed by Warnier et al., in intradermal injection in mice for immunization against P1A (*Int. J. Cancer*, 67:303-310, 1996).

The invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of each of the previously discussed coding sequences. Other components may be added, as desired, as long as the previously mentioned sequences, which are required, are included.

It will also be recognized that the invention embraces the use of the above described, LEDGF cDNA sequence containing expression vectors, to transfect host cells and cell lines, be these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells such as mouse, hamster, pig, goat, primate, etc. They may be of a wide variety of tissue types, and include primary cells and cell lines. Specific examples include dendritic cells, U293 cells, peripheral blood leukocytes, bone marrow stem cells and embryonic stem cells. The invention also permits the construction of LEDGF gene "knock-outs" in cells and in animals, providing materials for studying certain aspects of LEDGF

activity.

The invention also provides isolated polypeptides (including whole proteins and partial proteins), encoded by the foregoing LEDGF nucleic acids, and include the polypeptide of SEQ ID NO:2 and unique fragments thereof. Such polypeptides are useful, for example, alone or as fusion proteins to stimulate cell proliferation, to maintain cell survival, to generate antibodies, as components of an immunoassay, etc. polypeptides can be isolated from biological samples including tissue or cell homogenates, and can also be expressed recombinantly in a variety of prokaryotic and eukaryotic expression systems by constructing an expression vector appropriate to the expression system, introducing the expression vector into the expression system, and isolating the recombinantly expressed protein. Short polypeptides, including antigenic peptides (such as are presented by MHC molecules on the surface of a cell for immune recognition) also can be synthesized chemically using well-established methods of peptide synthesis.

A unique fragment of an LEDGF polypeptide, in general, has the features and characteristics of unique fragments as discussed above in connection with nucleic acids. As will be recognized by those skilled in the art, the size of the unique fragment will depend upon factors such as whether the fragment constitutes a portion of a conserved protein domain. Thus, some regions of SEQ ID NO:2 will require longer segments to be unique while others will require only short segments, typically between 5 and 12 amino acids (e.g. 5, 6, 7, 8, 9, 10, 11 and 12 amino acids long or more, including each integer up to the full length, 530 amino acids long). Virtually any segment of SEQ ID NO:2, excluding the ones that share identity with HDGF (SEQ ID NOs:9, 10, 11 and 12) and the partial human autoantigen DFS70 (SEQ ID Nos:22), that is 9 or more amino acids in length will be unique.

Unique fragments of a polypeptide preferably are those fragments which retain a distinct functional capability of the polypeptide. Functional capabilities which can be retained in a unique fragment of a polypeptide include interaction with antibodies, interaction with other polypeptides or fragments thereof, selective binding to receptors, and protein synthesis stimulating activity. One important activity is the ability to act as a signature for identifying the polypeptide. Another is the ability to complex with HLA and to provoke in a human an immune response. Those skilled in the art are well versed in methods for selecting unique amino acid sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from non-family members. A comparison of

the sequence of the fragment to those on known databases typically is all that is necessary.

The invention embraces variants of the LEDGF polypeptides described above. As used herein, a "variant" of a LEDGF polypeptide is a polypeptide which contains one or more modification to the primary amino acid sequence of a LEDGF polypeptide. Modifications which create a LEDGF polypeptide variant are typically made to the nucleic acid which encodes the LEDGF polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and addition of amino acids or non-amino acid moieties to: 1) reduce or eliminate an activity of a LEDGF polypeptide; 2) enhance a property of a LEDGF polypeptide, such as protein stability in an expression system or the stability of protein-protein binding; 3) provide a novel activity or property to a LEDGF polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety; or 4) to provide equivalent or better binding to a LEDGF polypeptide receptor or other molecule (e.g., heparin). Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a fatty acid, and the like. Modifications also embrace fusion proteins comprising all or part of the LEDGF amino acid sequence. One of skill in the art will be familiar with methods for predicting the effect on protein conformation of a change in protein sequence, and can thus "design" a variant LEDGF polypeptide according to known methods. One example of such a method is described by Dahiyat and Mayo in *Science* 278:82-87, 1997, whereby proteins can be designed *de novo*. The method can be applied to a known protein to vary a only a portion of the polypeptide sequence. By applying the computational methods of Dahiyat and Mayo, specific variants of a cancer associated antigen polypeptide can be proposed and tested to determine whether the variant retains a desired conformation.

Variants can include LEDGF polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a LEDGF polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

Mutations of a nucleic acid which encodes a LEDGF polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such a hairpins or

loops, which can be deleterious to expression of the variant polypeptide.

Mutations can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which mutation provides a variant polypeptide with the desired properties. Further mutations can be made to variants (or to non-variant LEDGF polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., *E. coli*, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a LEDGF gene or cDNA clone to enhance expression of the polypeptide.

The skilled artisan will realize that conservative amino acid substitutions may be made in LEDGF polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e., the variants retain the functional capabilities of the LEDGF polypeptides. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Exemplary functionally equivalent variants of the LEDGF polypeptides include conservative amino acid substitutions of SEQ ID NO:2. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

Thus functionally equivalent variants of LEDGF polypeptides, i.e., variants of LEDGF polypeptides which retain the function of the natural LEDGF polypeptides, are contemplated by the invention. Conservative amino-acid substitutions in the amino acid sequence of LEDGF polypeptides to produce functionally equivalent variants of LEDGF polypeptides typically are made by alteration of a nucleic acid encoding LEDGF polypeptides (SEQ ID NOs:1, 13). Such substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed



mutation, site-directed mutagenesis according to the method of Kunkel (Kunkel, *Proc. Nat. Acad. Sci. U.S.A.* 82: 488-492, 1985), or by chemical synthesis of a gene encoding a LEDGF polypeptide. The activity of functionally equivalent fragments of LEDGF polypeptides can be tested by cloning the gene encoding the altered LEDGF polypeptide into a bacterial or  
5 mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered LEDGF polypeptide, and testing for a functional capability of the LEDGF polypeptides as disclosed herein.

The invention as described herein has a number of uses, some of which are described elsewhere herein. First, the invention permits isolation of LEDGF polypeptides. A variety of  
10 methodologies well-known to the skilled practitioner can be utilized to obtain isolated LEDGF molecules. The polypeptide may be purified from cells which naturally produce the polypeptide by chromatographic means or immunological recognition. Alternatively, an expression vector may be introduced into cells to cause production of the polypeptide. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to  
15 cause production of the encoded polypeptide. Translation of LEDGF mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to produce LEDGF polypeptides. Those skilled in the art also can readily follow known methods for isolating LEDGF polypeptides. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography and immune-affinity  
20 chromatography.

The invention also provides, in certain embodiments, "dominant negative" polypeptides derived from LEDGF polypeptides. A dominant negative polypeptide is an inactive variant of a protein, which, by interacting with the cellular machinery, displaces an active protein from its interaction with the cellular machinery or competes with the active  
25 protein, thereby reducing the effect of the active protein. For example, a dominant negative receptor which binds a ligand but does not transmit a signal in response to binding of the ligand can reduce the biological effect of expression of the ligand. Likewise, a dominant negative catalytically-inactive kinase which interacts normally with target proteins but does not phosphorylate the target proteins can reduce phosphorylation of the target proteins in  
30 response to a cellular signal. Similarly, a dominant negative transcription factor which binds to a promoter site in the control region of a gene but does not increase gene transcription can reduce the effect of a normal transcription factor by occupying promoter binding sites without

increasing transcription.

The end result of the expression of a dominant negative polypeptide in a cell is a reduction in function of active proteins. One of ordinary skill in the art can assess the potential for a dominant negative variant of a protein, and using standard mutagenesis techniques to create one or more dominant negative variant polypeptides. For example, given the teachings contained herein of cancer associated antigens, especially those which are similar to known proteins which have known activities, one of ordinary skill in the art can modify the sequence of the cancer associated antigens by site-specific mutagenesis, scanning mutagenesis, partial gene deletion or truncation, and the like. See, e.g., U.S. Patent No. 5,580,723 and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. The skilled artisan then can test the population of mutagenized polypeptides for diminution in a selected and/or for retention of such an activity. Other similar methods for creating and testing dominant negative variants of a protein will be apparent to one of ordinary skill in the art.

The isolation of the LEDGF cDNA also makes it possible for the artisan to diagnose a disorder characterized by an aberrant expression of LEDGF. These methods involve determining expression of the LEDGF gene, and/or LEDGF polypeptides derived therefrom. In the former situation, such determinations can be carried out via any standard nucleic acid determination assay, including the polymerase chain reaction, or assaying with labeled hybridization probes as exemplified below. In the latter situation, such determination can be carried out via any standard immunological assay using, for example, antibodies which bind to the secreted LEDGF protein.

The invention also embraces isolated peptide binding agents which, for example, can be antibodies or fragments of antibodies having the ability to selectively bind to LEDGF polypeptides. Antibodies include polyclonal and monoclonal antibodies, prepared according to conventional methodology.

Significantly, as is well-known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark, W.R. (1986) The Experimental Foundations of Modern Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has

been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')<sub>2</sub> fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.

It is now well-established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of conspecific or heterospecific antibodies while retaining the epitopic specificity of the original antibody. This is most clearly manifested in the development and use of "humanized" antibodies in which non-human CDRs are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. Thus, for example, PCT International Publication Number WO 92/04381 teaches the production and use of humanized murine RSV antibodies in which at least a portion of the murine FR regions have been replaced by FR regions of human origin. Such antibodies, including fragments of intact antibodies with antigen-binding ability, are often referred to as "chimeric" antibodies.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for F(ab')<sub>2</sub>, Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric F(ab')<sub>2</sub> fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by

homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences. The present invention also includes so-called single chain antibodies.

Thus, the invention involves polypeptides of numerous size and type that bind specifically to LEDGF polypeptides, and complexes of both LEDGF polypeptides and their binding partners. These polypeptides may be derived also from sources other than antibody technology. For example, such polypeptide binding agents can be provided by degenerate peptide libraries which can be readily prepared in solution, in immobilized form, as bacterial flagella peptide display libraries or as phage display libraries. Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptides and non-peptide synthetic moieties.

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. m13, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent, for example, a completely degenerate or biased array. One then can select phage-bearing inserts which bind to the LEDGF polypeptide or a complex of LEDGF and a binding partner. This process can be repeated through several cycles of reselection of phage that bind to the LEDGF polypeptide or complex. Repeated rounds lead to enrichment of phage bearing particular sequences. DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear portion of the sequence that binds to the LEDGF polypeptide or complex can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Yeast two-hybrid screening methods also may be used to identify polypeptides that bind to the LEDGF polypeptides. Thus, the LEDGF polypeptides of the invention, or a fragment thereof, or complexes of LEDGF and a binding partner can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding partners of the LEDGF polypeptides of the invention. Such molecules can be used, as described, for screening assays, for purification protocols, for interfering directly with the functioning of LEDGF and for other purposes that will be apparent to those of ordinary skill

in the art.

A LEDGF polypeptide, or a fragment thereof, also can be used to isolate their native binding partners. Isolation of binding partners may be performed according to well-known methods. For example, isolated LEDGF polypeptides can be attached to a substrate, and then a solution suspected of containing an LEDGF binding partner may be applied to the substrate. If the binding partner for LEDGF polypeptides is present in the solution, then it will bind to the substrate-bound LEDGF polypeptide. The binding partner then may be isolated. Other proteins which are binding partners for LEDGF, may be isolated by similar methods without undue experimentation.

The invention also embraces determining an individual's susceptibility to developing cataracts. In determining an individual's susceptibility to developing cataracts, the level of anti-LEDGF antibodies in the individual is obtained. The level of the anti-LEDGF antibodies for the individual can be obtained by numerous art recognized methods. Typically, the anti-LEDGF antibody level is determined by immunoassays, such as enzyme-linked immunoassays, or other conventional techniques. The invention enables such techniques through isolation of LEDGF and epitopes thereof. The presence and level of anti-LEDGF antibodies can be determined as a measure of binding to isolated LEDGF or epitopes thereof. These techniques are performed on test samples obtained from the individual's bodily fluids, such as blood, lymph, saliva, urine and the like, tissues, or cultures from tissue biopsies. The preferred body fluid is blood and the preferred tissue is skin or buccal scraping.

The invention also involves comparing the anti-LEDGF antibody level for the individual with a control. The control can be of any art recognized type, such as reagents to be tested side by side with the test fluid or a predetermined value such as a color or a number. The predetermined value can be a single cut-off value, such as the median or mean anti-LEDGF antibody level for a control population. The control population preferably includes only individuals of a similar age group as the individual tested (e.g. within 5-10 years). The predetermined value can also be a range, for example, where the population used to obtain the anti-LEDGF antibody level to be used as the control, is divided equally (or unequally) into groups, such as a low-risk group and a high-risk group, or into quadrants, the lowest quadrant being individuals with the lowest risk and the highest quadrant being individuals with the highest risk. Thus, the predetermined value can depend upon the particular population selected. For example, an apparently healthy population (no detectable disease and no prior

history of cataracts) can have a different 'normal' range of anti-LEDGF antibody levels than will a population the members of which have had a prior cataract disorder. Accordingly, the predetermined values selected may take into account the category in which an individual falls. Appropriate ranges and categories can be selected with no more than routine experimentation by those of ordinary skill in the art.

For anti-LEDGF antibody levels, one important cut-off for a population of apparently healthy individuals is  $OD_{492} < 200$ . In characterizing risk, individuals with anti-LEDGF antibody levels equal to or higher than the foregoing mentioned cut-off value are more susceptible to developing a cataract than individuals with anti-LEDGF antibody levels below this value.

The invention also provides novel kits which could be used to measure the levels of the nucleic acids of the invention, expression products of the invention or anti-LEDGF antibodies. In the case of nucleic acid detection, pairs of primers for amplifying LEDGF nucleic acids can be included. The preferred kits would include controls such as known amounts of nucleic acid probes, LEDGF epitopes (such as LEDGF expression products) or anti-LEDGF antibodies, as well as instructions or other printed material. In certain embodiments the printed material can characterize risk of developing a cataract based upon the outcome of the assay. Additionally, anti- $\beta$ -crystallin antibodies and  $\beta$ -crystallin epitopes can also be included for control purposes. The reagents may be packaged in containers and/or coated on wells in predetermined amounts, and the kits may include standard materials such as labeled immunological reagents (such as labeled anti-IgG antibodies) and the like. One kit is a packaged polystyrene microtiter plate coated with LEDGF protein and a container containing labeled anti-human IgG antibodies. A well of the plate is contacted with, for example, serum, washed and then contacted with the anti-IgG antibody. The label is then detected. A kit embodying features of the present invention, generally designated by the numeral 11, is illustrated in Figure 5. Kit 11 is comprised of the following major elements: packaging 15, an agent of the invention 17, a control agent 19 and instructions 21. Packaging 15 is a box-like structure for holding a vial (or number of vials) containing an agent of the invention 17, a vial (or number of vials) containing a control agent 19, and instructions 21. Individuals skilled in the art can readily modify packaging 15 to suit individual needs.

The invention also involves a method for treating subjects at risk of developing cataracts (i.e. with an abnormally elevated level of anti-LEDGF antibody) or subjects having

had capsulotomy, to prevent the formation of future cataracts. This method involves the administration of an agent to 'tolerize' the subject against LEDGF epitopes. It has been described in the art that by administering an antigen to a mammal over an extended period of time or in certain doses and regimens, Th1-type immunoreactive responses to the antigen are suppressed leading to tolerization. A preferred agent of the invention administered is a LEDGF polypeptide encoded by the isolated nucleic acid molecules of claim 1, 2 or 3. The preferred mode of its administration is oral. Another preferred agent for the purpose of tolerization is a LEDGF polypeptide encoded by the isolated nucleic acid molecules of claim 1, 2 or 3 conjugated to an antibody. The preferred mode of administration for this agent is *intravenously*. The agents described herein are administered in effective amounts. An effective amount of the agent is that dosage sufficient to reduce a subject's immune response against LEDGF polypeptides, and thus reduce anti-LEDGF serum antibody levels in order to prevent opacity formation in the crystalline lens of the subject.

The invention also provides methods to measure the level of LEDGF expression in a subject. This can be performed by first obtaining a test sample from the subject. The test sample can be tissue or biological fluid. Tissues include lens epithelium, kidney and skin, and biological fluids include blood, aqueous humor and tears. Both invasive and non-invasive techniques can be used to obtain such samples and are well documented in the art. At the molecular level both PCR and Northern blotting can be used to determine the level of LEDGF mRNA using products of this invention described earlier, and protocols well known in the art that are found in references which compile such methods. At the protein level, LEDGF expression can be determined using either polyclonal or monoclonal anti-LEDGF sera in combination with standard immunological assays. The preferred methods will compare the measured level of LEDGF expression of the test sample to a control. A control can include a known amount of a nucleic acid probe, a LEDGF epitope (such as a LEDGF expression product), or a similar test sample of a subject with a control or 'normal' level of LEDGF expression.

The invention also embraces a method for treating subjects with cancers expressing LEDGF. It involves first determining whether the cancer expresses LEDGF. If it does, then an effective amount of an agent which interferes with LEDGF mediated activity can be administered to the subject in order to slow down, or inhibit, the proliferation of the cancer cells expressing LEDGF. Such agents include antisense oligonucleotides (e.g. to the nucleic

acid of SEQ ID NO:1) or a polypeptide that binds to LEDGF (such as an anti-LEDGF antibody). The mode of administration and dosage of the agent will vary with the particular stage of the condition being treated, the age and physical condition of the subject being treated, the duration of the treatment, the nature of the concurrent therapy (if any), the specific route of administration, and the like factors within the knowledge and expertise of the health practitioner. In preferred embodiments of the invention cancers expressing LEDGF include: biliary tract cancer; brain cancer, including glioblastomas and medulloblastomas; breast cancer; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; gastric cancer; hematological neoplasms, including acute lymphocytic and myelogenous leukemia; multiple myeloma; AIDS associated leukemias and adult T-cell leukemia lymphoma; intraepithelial neoplasms, including Bowen's disease and Paget's disease; liver cancer; lung cancer; lymphomas, including Hodgkin's disease and lymphocytic lymphomas; neuroblastomas; oral cancer, including squamous cell carcinoma; ovarian cancer, including those arising from epithelial cells, stromal cells, germ cells and mesenchymal cells; pancreas cancer; prostate cancer; rectal cancer; sarcomas, including leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma and osteosarcoma; skin cancer, including melanoma, Kaposi's sarcoma, basocellular cancer and squamous cell cancer; testicular cancer, including germinal tumors (seminoma, non-seminoma[teratomas, choriocarcinomas]), stromal tumors and germ cell tumors; thyroid cancer, including thyroid adenocarcinoma and medullar carcinoma; and renal cancer including adenocarcinoma and Wilms tumor. In other embodiments cancers expressing LEDGF are cancers aberrantly expressing LEDGF. Aberrant expression is overexpression of LEDGF.

In certain embodiments the agent can be administered, as mentioned earlier, in combination with other anti-cancer agents such as: Acivicin; Aclarubicin; Acodazole Hydrochloride; Acronine; Adozelesin; Aldesleukin; Altretamine; Ambomycin; Ametantrone Acetate; Aminoglutethimide; Amsacrine; Anastrozole; Anthramycin; Asparaginase; Asperlin; Azacitidine; Azetepa; Azotomycin; Batimastat; Benzodepa; Bicalutamide; Bisantrone Hydrochloride; Bisnafide Dimesylate; Bizelesin; Bleomycin Sulfate; Brequinar Sodium; Bropiramine; Busulfan; Cactinomycin; Calusterone; Caracemide; Carbetimer; Carboplatin; Carmustine; Carubicin Hydrochloride; Carzelesin; Cedefingol; Chlorambucil; Cirolemycin; Cisplatin; Cladribine; Crisnatol Mesylate; Cyclophosphamide; Cytarabine; Dacarbazine; Dactinomycin; Daunorubicin Hydrochloride; Decitabine; Dexormaplatin; Dezaguanine;



Dezaguanine Mesylate; Diaziquone; Docetaxel; Doxorubicin; Doxorubicin Hydrochloride;  
 Droloxifene; Droloxifene Citrate; Dromostanolone Propionate; Duazomycin; Edatrexate;  
 Eflornithine Hydrochloride; Elsamitrucin; Enloplatin; Enpromate; Epiropidine; Epirubicin  
 Hydrochloride; Erbulozole; Esorubicin Hydrochloride; Estramustine; Estramustine Phosphate  
 5 Sodium; Etanidazole; Etoposide; Etoposide Phosphate; Etoprine; Fadrozole Hydrochloride;  
 Fazarabine; Fenretinide; Floxuridine; Fludarabine Phosphate; Fluorouracil; Flurocitabine;  
 Fosquidone; Fostriecin Sodium; Gemcitabine; Gemcitabine Hydrochloride; Hydroxyurea;  
 Idarubicin Hydrochloride; Ifosfamide; Ilmofofosine; Interferon Alfa-2a; Interferon Alfa-2b;  
 Interferon Alfa-n1; Interferon Alfa-n3; Interferon Beta- I a; Interferon Gamma- I b; Iproplatin;  
 10 Irinotecan Hydrochloride; Lanreotide Acetate; Letrozole; Leuprolide Acetate; Liarozole  
 Hydrochloride; Lometrexol Sodium; Lomustine; Losoxantrone Hydrochloride; Masoprocol;  
 Maytansine; Mechlorethamine Hydrochloride; Megestrol Acetate; Melengestrol Acetate;  
 Melfalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate Sodium; Metoprine;  
 Meturedopa; Mitindomide; Mitocarcin; Mitocromin; Mitogillin; Mitomalcin; Mitomycin;  
 15 Mitosper; Mitotane; Mitoxantrone Hydrochloride; Mycophenolic Acid; Nocodazole;  
 Nogalamycin; Ormaplatin; Oxisuran; Paclitaxel; Pegaspargase; Peliomycin; Pentamustine;  
 Peplomycin Sulfate; Perfosfamide; Pipobroman; Pipsulfan; Piroxantrone Hydrochloride;  
 Plicamycin; Plomestane; Porfimer Sodium; Porfiromycin; Prednimustine; Procarbazine  
 Hydrochloride; Puromycin; Puromycin Hydrochloride; Pyrazofurin; Riboprine; Rogletimide;  
 20 Safingol; Safingol Hydrochloride; Semustine; Simtrazene; Sparfosate Sodium; Sparsomycin;  
 Spirogermanium Hydrochloride; Spiromustine; Spiroplatin; Streptonigrin; Streptozocin;  
 Sulofenur; Talisomycin; Tecogalan Sodium; Tegafur; Teloxantrone Hydrochloride;  
 Temoporfin; Teniposide; Teroxirone; Testolactone; Thiamiprine; Thioguanine; Thiotepa;  
 Tiazofurin; Tirapazamine; Topotecan Hydrochloride; Toremifene Citrate; Trestolone Acetate;  
 25 Triciribine Phosphate; Trimetrexate; Trimetrexate Glucuronate; Triptorelin; Tubulozole  
 Hydrochloride; Uracil Mustard; Uredepa; Vapreotide; Verteporfin; Vinblastine Sulfate;  
 Vincristine Sulfate; Vindesine; Vindesine Sulfate; Vinepidine Sulfate; Vinglycinate Sulfate;  
 Vinleurosine Sulfate; Vinorelbine Tartrate; Vinrosidine Sulfate; Vinzolidine Sulfate;  
 Vorozole; Zeniplatin; Zinostatin; Zorubicin Hydrochloride.

30 The invention also contemplates methods for decreasing LEDGF activity in a subject.  
 Such subjects may have abnormally high LEDGF levels, for example, such subjects may have  
 conditions characterized by unwanted proliferation of cells, and in tissues and cells not

usually expressing LEDGF at all or typically at lower levels (e.g. cancer cells). In other embodiments, LEDGF activity is decreased in order to slow down or inhibit such unwanted proliferation (e.g. in disorders such as restenosis and psoriasis). Decrease in LEDGF activity in the subject can be accomplished by the administration of an agent that interferes with LEDGF mediated activity. Such agents bind to the nucleic acid of SEQ ID NO:1 or expression products thereof, in amounts effective to slow down or inhibit the proliferation of cells expressing LEDGF. A preferred agent is an antisense oligonucleotide or a polypeptide that binds to LEDGF (such as an anti-LEDGF antibody). As in the method for treating cancers expressing LEDGF, the mode of administration and dosage of the agent will vary with the particular stage of the condition being treated, the age and physical condition of the subject being treated, the duration of the treatment, the nature of the concurrent therapy (if any), the specific route of administration, and the like factors within the knowledge and expertise of the health practitioner.

The invention also contemplates methods for preventing the differentiation of cells *in vitro*. Cells *in vitro* are contacted with an agent that selectively binds to the products of this invention, such as the isolated nucleic acid of claim 1, 2 or 3, or its expression products thereof, in an amount effective to decrease LEDGF mediated activity in the cell and inhibit its differentiation. The agent can be an antisense oligonucleotide or a polypeptide (anti-LEDGF antibody), as described earlier. Such methods can be very useful in preventing the differentiation of a number of mammalian cell types *in vitro*, for example, mouse embryonic stem cells used in "knock-out" experiments, hemopoietic stem cells, etc.

By using the methodology as described in the preceding paragraphs, but with increased effective amounts of the agent, the invention also provides for a method to induce cell-death both *in vivo* and *in vitro*. In this instance, the agents that interfere with LEDGF mediated activity are administered in amounts effective to induce cell-death of cells expressing LEDGF. For *in vivo* treatments localized administration is called for in this embodiment.

The invention also embraces methods for increasing cell proliferation by contacting a cell expressing a LEDGF receptor with the isolated nucleic acid of claim 1, 2 or 3, or expression products thereof, in an amount effective to increase LEDGF activity in the cell and promote its proliferation. Such methods can be very useful in the expansion of mammalian cell cultures, including differentiated cells, and to promote the proliferation of cells involved in wound healing, both *in vivo* and *in vitro*. Thus, the invention also involves methods for

treating a subject with a wound to induce wound healing by contacting the wound with an agent that increases LEDGF mediated activity in amounts sufficient to promote cell proliferation and wound healing. The preferred agent is LEDGF or an active fragment thereof. A cell expressing a LEDGF receptor is a cell that upon contact with LEDGF increases its protein synthesis.

The invention also provides methods for inhibiting cell-death induced by environmental stress of a cell which expresses a LEDGF receptor, by contacting it with the isolated nucleic acid of claim 1, 2 or 3, or expression products thereof, in an amount effective to increase LEDGF mediated activity in the cell and enhance its survival ability, both *in vivo* and *in vitro*. The lifespan of a cell under environmental stress is significantly shorter when compared to the lifespan of a cell under no such stress. This can be easily detected by placing a number of cells under a form of environmental stress and comparing their survival (numbers) to an identical number of cells free from any stress over a period of time. The amount of the foregoing agent(s) of the invention sufficient to inhibit cell-death, is the amount sufficient to extend the lifespan of the mammalian cell under environmental stress toward comparable lifespan lengths of cells free from any environmental stress. Such methods can be used to protect cells from environmental insults, such as increased temperatures (e.g., fever), physical trauma, oxidative, osmotic and chemical stress, and UV irradiation. In a preferred embodiment of this invention cells under environmental stress are skin fibroblasts, and topical skin applications with an agent that increases LEDGF mediated activity in amounts sufficient to promote cell survival are contemplated. In another preferred embodiment cells under environmental stress are neuronal cells. The preferred agent is LEDGF or an active fragment thereof.

The invention also provides methods for increasing heat-shock protein activity in a cell, by contacting it with the isolated nucleic acid of claim 1, 2 or 3, or expression products thereof, in an amount effective to increase LEDGF mediated activity in the cell and to increase heat-shock protein activity in the cell, both *in vivo* and *in vitro*. By "increased heat-shock protein activity" it is meant to include both increases in a heat-shock protein mRNA expression and heat-shock protein polypeptide production. In preferred embodiments  $\alpha\beta$ -crystallin and HSP-27 activity is increased. The preferred agent is also LEDGF or an active fragment thereof.

The pharmaceutical preparations, as described above, are administered in effective

amounts. The effective amount will depend upon the mode of administration, the particular condition being treated and the desired outcome. It will also depend upon, as discussed above, the stage of the condition, the age and physical condition of the subject, the nature of concurrent therapy, if any, and like factors well known to the medical practitioner. For therapeutic applications, it is that amount sufficient to achieve a medically desirable result. In some cases this is a decrease in cell proliferation. In other cases, it is an increase in cell proliferation. In still other cases, it is a decrease in a subject's immune hypersensitivity to LEDGF as evidenced by a decrease in circulating anti-LEDGF antibodies.

Generally, doses of active compounds of the present invention would be from about 0.01 mg/kg per day to 1000 mg/kg per day. It is expected that doses ranging from 50-500 mg/kg will be suitable. A variety of administration routes are available. The methods of the invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects. Such modes of administration include oral, rectal, topical, nasal, interdermal, or parenteral routes. The term "parenteral" includes subcutaneous, intravenous, intramuscular, or infusion. Intravenous or intramuscular routes are not particularly suitable for long-term therapy and prophylaxis. They could, however, be preferred in emergency situations. Oral administration will be preferred for prophylactic treatment because of the convenience to the patient as well as the dosing schedule. When peptides are used therapeutically, in certain embodiments a desirable route of administration is by pulmonary aerosol. Techniques for preparing aerosol delivery systems containing peptides are well known to those of skill in the art. Generally, such systems should utilize components which will not significantly impair the biological properties of the antibodies, such as the paratope binding capacity (see, for example, Sciarra and Cutie, "Aerosols," in Remington's Pharmaceutical Sciences, 18th edition, 1990, pp 1694-1712; incorporated by reference). Those of skill in the art can readily determine the various parameters and conditions for producing antibody or peptide aerosols without resort to undue experimentation.

Compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active agent. Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as a syrup, elixir or an emulsion.

Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like. Lower doses will result from other forms of administration, such as intravenous administration. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits. Multiple doses per day are contemplated to achieve appropriate systemic levels of compounds.

The LEDGF polypeptides or fragments thereof may be combined, optionally, with a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid filler, diluents or encapsulating substances which are suitable for administration into a human. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.

When administered, the pharmaceutical preparations of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptably compositions. Such preparations may routinely contain salt, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention. Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the

like. Also, pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.

LEDGF polypeptides preferably are produced recombinantly, although such polypeptides may be isolated from biological extracts. Recombinantly produced LEDGF polypeptides include chimeric proteins comprising a fusion of a LEDGF protein with another polypeptide, e.g., a polypeptide capable of providing or enhancing protein-protein binding, sequence specific nucleic acid binding (such as GAL4), enhancing stability of the LEDGF polypeptide under assay conditions, or providing a detectable moiety, such as green fluorescent protein. A polypeptide fused to a LEDGF polypeptide or fragment may also provide means of readily detecting the fusion protein, e.g., by immunological recognition or by fluorescent labeling.

Various techniques may be employed for introducing nucleic acids of the invention into cells, depending on whether the nucleic acids are introduced *in vitro* or *in vivo* in a host. Such techniques include transfection of nucleic acid-CaPO<sub>4</sub> precipitates, transfection of nucleic acids associated with DEAE, transfection with a retrovirus including the nucleic acid of interest, liposome mediated transfection, and the like. For certain uses, it is preferred to target the nucleic acid to particular cells. In such instances, a vehicle used for delivering a nucleic acid of the invention into a cell (e.g., a retrovirus, or other virus; a liposome) can have a targeting molecule attached thereto. For example, a molecule such as an antibody specific for a surface membrane protein on the target cell or a ligand for a receptor on the target cell can be bound to or incorporated within the nucleic acid delivery vehicle. For example, where liposomes are employed to deliver the nucleic acids of the invention, proteins which bind to a surface membrane protein associated with endocytosis may be incorporated into the liposome formulation for targeting and/or to facilitate uptake. Such proteins include capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half life, and the like. Polymeric delivery systems also have been used successfully to deliver nucleic acids into cells, as is known by those skilled in the art. Such systems even permit oral delivery of nucleic acids.

Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the anti-inflammatory agent, increasing convenience to the subject and the physician. Many types of release

delivery systems are available and known to those of ordinary skill in the art. They include polymer base systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides.

Microcapsules of the foregoing polymers containing drugs are described in, for example, U.S.

5 Patent 5,075,109. Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono- di- and tri-glycerides; hydrogel release systems; systatic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients; partially fused implants; and the like. Specific examples include, but are not limited to: (a)  
10 erosional systems in which the anti-inflammatory agent is contained in a form within a matrix such as those described in U.S. Patent Nos. 4,452,775, 4,667,014, 4,748,034 and 5,239,660 and (b) difusional systems in which an active component permeates at a controlled rate from a polymer such as described in U.S. Patent Nos. 3,832,253, and 3,854,480. In addition, pump-based hardware delivery systems can be used, some of which are adapted for implantation.

15 Use of a long-term sustained release implant may be particularly suitable for treatment of chronic conditions. Long-term release, as used herein, means that the implant is constructed and arranged to deliver therapeutic levels of the active ingredient for at least 30 days, and preferably 60 days. Long-term sustained release implants are well-known to those of ordinary skill in the art and include some of the release systems described above.

20

### Examples

#### Experimental Procedures

#### Construction and screening of the cDNA library

One hundred human lens capsulotomy specimens were obtained from Dr. Joseph  
25 Horwitz, Jules Stein Eye Institute, UCLA. Total RNA extraction, mRNA purification and cDNA construction were performed according to methods well known in the art. The double stranded cDNAs were subcloned into the EcoRI and XhoI sites of the Uni-ZAP™ XR vector of the ZAP-cDNA Synthesis Kit (Stratagene, La Jolla, CA) as described in the manual of the manufacturer. The library titre was  $4 \times 10^6$  plaque forming units per 1 mg of cDNA. The  
30 background of this library was less than 2%. The library was screened with Ab probes in human sera (1:200 dilution) from cataract patients. The second Ab used was goat anti-human IgG labeled with horseradish peroxidase (1:5,000 dilution; Kirkegaard & Perry Laboratories,

DNA sequence was determined in the Brigham and Women's Hospital Automated Sequencing and Genotyping Facility. Molecular biological techniques such as restriction enzyme treatment, subcloning, DNA extraction, bacterial culture and purification of DNA fragments were performed according to methods well known in the art and as described in references which compile such methods. Computer analyses of protein and DNA sequences was done using the GCG "Idea" program (Kanehisa, National Cancer Institute, Frederick, MD, 1986). Restriction endonucleases, expression vectors, and modifying enzymes were purchased from commercial sources (Gibco-BRL). Sequencing vectors for DNA were purchased from Stratagene (La Jolla, CA). Oligonucleotide probes were purchased from Lofstrand Labs Limited (Gaithersburg, MD).

25 Poly(A)-RNA for northern blot analysis was isolated from mouse cultured lens epithelial cell and from various mouse organs (liver; spleen, thymus, lymphocytes, heart, kidney, lung, brain, and muscles). Approximately 5µg of each poly(A)RNA was applied to a well of 1% agarose-formaldehyde gel electrophoresis. The resulting RNAs were blotted to a nitrocellulose membrane (Optitran™; Schleicher & Schuell, Keene, NH). The RNA on the membrane was hybridized at 42°C in 50% formamide with <sup>32</sup>P-labeled HLC10 cDNA probe. Duplicate lanes of RNA, run in parallel, were hybridized with <sup>32</sup>P-labeled β-actin cDNA probe.

Mouse LECs were grown in a six well-plate ( $5 \times 10^6$  cells/well) in DMEM containing 10% FCS. For studies of protein synthesis, we used [ $^{35}\text{S}$ ]-methionine (New England Nuclear-



NEN, Boston, MA) incorporation. Medium was aspirated from the wells and washed twice by gently swirling with methionine/cysteine-free DMEM-medium. Cells were starved for 30 minutes at 37°C to deplete intra-cellular pools of methionine. Then <sup>35</sup>S-methionine (150μCi/ml;) was added in the medium and incubated for 12 hr.

- 5           Cells were trypsinized (0.25% trypsin and 1 mM EDTA-Na in PBS) for 5-10 minutes at room temperature and separated from the bottom of flask. After washing with PBS, the cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Gibco-BRL) supplemented with heat-inactivated fetal calf serum (FCS) (10% for mouse LECs and 20% for human LECs), 1 mM L-glutamine, 25 mM HEPES, 100 unit/ml penicillin, 100 μg/ml streptomycin (Cat. No. 1196S-050; Gibco-BRL) at 37°C in a 5% CO<sub>2</sub> atmosphere. The medium was replaced every third day (Ibaraki, I., et al., *Exp. Eye Res.*, 1997, 64:229-238; Reddy et al., *Exp. Eye Res.*, 1988, 47:465-78).
- 10

#### Expression of LEDGF in a Prokaryotic Vector and its Purification

- 15           The plasmid of identified full length cDNA clone (HLC10) was digested with restriction enzymes BamHI and EcoRI (Gibco-BRL), and the fragment was ligated into the BamHI and EcoRI sites of a pGEX-2T vector (Pharmacia Biotech, Piscataway, NJ). The construct was transfected in *E.coli* (BL21). The transformed *E. coli* was cultured in 500 ml of LB-ampicillin medium and incubated at 35°C with shaking until optical density of *E. coli* reached to 0.5 OD<sub>490</sub>. Then, isopropyl b-D-thiogalactoside (IPTG) (Pharmacia Biotech, Piscataway, NJ) was added at final concentration 100μM and further incubated 5-6 hr. Bacteria were centrifuged at 6,000 rpm for 20 min at 4°C. Pellet was suspended in 25 ml of the lysis buffer (50mM Tris-HCL, pH8.0; 200mM NaCl, 1.5mM EDTA, and 1mM PMSF) followed by addition of lysozyme (1mg/ml) and incubated on ice for 15 min. Then, Triton X-100 (Sigma Chemicals) was added at the final concentration of 1% and mixed gently for 30 min to aid the solubilization of fusion protein. The lysate was sonicated with short bursts. The sonicate was centrifuged at 12,000 rpm for 10 min at 4°C. Supernatant was treated with 10 mM MgSO<sub>4</sub> and 2mM ATP at 37°C for 10min to disrupt the association of the 70kDa protein to glutathione Sepharose 4B (Pharmacia Biotech) during affinity chromatography. To purify the fusion protein, the supernatant was incubated over night with 2ml of the 50% slurry of Glutathione Sepharose 4B at 4°C. Suspension was centrifuge at 500g for 5 minutes. Pellet was washed 4 times in lysis buffer and the fusion protein was eluted with Glutathione elution
- 20
- 25
- 30

buffer. The identity of the eluted protein was confirmed by SDS-PAGE and immunoblotting using GST Ab (Pharmacia Biotech). Protein was dialyzed against 2,000 volumes of PBS at 4°C. Protein concentration was determined using the Bradford method (Bradford, *Anal. Biochem.*, 1976, 72:248-254). Expression in the above vector produced a relatively low level of LEDGF. To remove the 5'-noncoding region (310 bps), we prepared a construct as follows. First we created a BamHI site just before the initiation site ATG (311 nucleotide of SEQ ID NO:1) at the 5'-noncoding region (Primer: 5'-ccccgcatcctgactcgcgattcaaacct-3': SEQ ID NO:19), and an EcoRI site (Primer: 5'-tcttgaattctgtagctgcaggtcgctcctct-3': SEQ ID NO:20) at the 3'-end. This fragment, 576 bp long, was ligated into the pGEX2T vector (Pharmacia Biotech) between the BamHI and EcoRI sites. This recombinant plasmid was amplified and the expression of LEDGF assayed by SDS-PAGE and immunoblotting using GST Ab. To achieve full length LEDGF, we generated another construct where the original LEDGF cDNA was cut with EcoRI and XhoI (Gibco-BRL) and the resulting fragment of 2,153 bp was ligated into the EcoRI site of the previous construct. This construct did not contain the 5'-noncoding region, but it had an entire coding sequence. The construct was transfected into *E. coli* (BL21), and LEDGF expression was analyzed with anti-LEDGF Abs (C- and N-terminal) as well as with GST Ab (Pharmacia Biotech). The expressed protein constituted more than 10% of the total bacterial protein. The LEDGF was purified directly from the bacterial lysate using the affinity matrix Glutathione Sepharose<sup>®</sup> 4B (Pharmacia Biotech). GST-LEDGF was reduced with glutathione for the elution of the fusion protein from the affinity matrix. The eluted fusion protein, under mild and non-denaturing conditions, was cleaved with thrombin protease. The glutathione was removed by passage through the affinity matrix Glutathione Sepharose<sup>®</sup> 4B. The detailed protocol is described in the manual provided by the supplier (Pharmacia Biotech).

#### Cell Transformation using Mammalian Expression Vectors

A fragment of LEDGF cDNA clone spanning the entire coding sequence was subcloned into a pcDNA3 mammalian expression vector (Invitrogen, Carlsbad, CA), at the EcoRI site. This expression vector had a CMV (human cytomegalovirus) promoter which drove the expression of the inserted gene. Also it had a neomycin-selectable marker, expressed by the SV40 promoter, and used for the selection of stable transformed cell lines in the presence of G418 (geneticin, Sigma Chemical Co., St Louis, MO). LECs and COS7 cells

-41-

were plated at a density of  $5 \times 10^5$  cells per 60 mm dish. On the next day, media were replaced with 6 ml of fresh DMEM with 10% FCS. After a 4 hr incubation, these cells were transfected using the calcium phosphate method as suggested. The transfected cells were further incubated in presence of geneticin at 500  $\mu\text{g/ml}$  for up to 30 days. Cells transfected with pcDNA3 vector served as a control.

### Immunization of Animals

Mice (Harlan Sprague-Dawley, Indianapolis, IN) were injected with 100  $\mu\text{g}$  LEDGF emulsified with CFA (Gibco-BRL, Bethesda, MD) at base of the tail. Subsequently booster injections, each at a dose of 100  $\mu\text{g}$  emulsified with IFA (Gibco-BRL), were carried out biweekly. The mice were euthanized by the 5th week, and serum was obtained from blood drawn from the hearts. We also immunized 2 rabbits (Harlan Sprague-Dawley) with 5.0 mg of each synthetic peptide or fusion protein emulsified with CFA (total volume 0.2 ml), and we injected these Ags into the backs of rabbits; two booster injections of 2.0 mg Ag emulsified with IFA were given at two week intervals. The peptides were conjugated with keyhole-limpet hemocyanin using the formaldehyde method (Harlow and Lane, *Antibodies: A Laboratory manual*. Cold Spring Harbor Laboratory Press. 1988, pp. 471-511), and dialyzed over night in the PBS prior to emulsification. The rabbit serum collection was five weeks after the first injection.

### Phosphorylation of LEDGF

Mouse LECs ( $5 \times 10^6$  cells) were cultured in  $\text{PO}_4$ -free DMEM (Gibco-BRL/LTI, Rockville, Maryland) supplemented with 3% dialyzed FCS and starved for 15 minutes at  $37^\circ\text{C}$ . Inorganic  $^{32}\text{P}$ -orthophosphate (500  $\mu\text{Ci/ml}$ ; NEN) adjusted to HEPES-buffer, was added and the cells were kept in culture for another 2 hrs. Cells were precipitated by centrifugation (1,200 rpm for 10 minutes), lysed with Nonidet P-40 lysis medium (Sigma Chemical Co. St Louis, MO) at the end of the labeling, and prepared for immunoprecipitation. Anti-LEDGF Abs (100  $\mu\text{l}$ ) were added and incubated overnight at  $4^\circ\text{C}$ . The precipitates were washed three times with PBS, were dissolved in SDS-PAGE buffer, and applied to the SDS-PAGE (8% polyacrylamide). One gel was used for immunostaining with anti-LEDGF Ab; the other gel was used for autoradiography, after staining it with Coomassie Brilliant Blue R-250 (Schwarz/Mann Biotech. Cleveland, OH) and drying it.

### ELISA Analysis

Antibody titration was carried out by the indirect enzyme-linked immunosorbent assay (ELISA). Ninety six-well microtiter plates (Dynatech Laboratories, Alexandria, VA) were coated with LEDGF polypeptides (0.5mg/100ml in sodium carbonate buffer, pH 9.3) and left overnight at 4°C. The plates were then washed 3 times with PBS containing 0.05% Tween-20 and blocked with 5% dry milk for 2 hrs at 37 °C. The plates were washed and incubated again overnight at 4 °C with test sera samples (diluted 1:10<sup>4</sup>-1:10<sup>7</sup> in PBS with 1% dry milk). The plates were washed, and 100µl of peroxidase-conjugated goat anti-human IgG(Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) at 1:2,000 dilution in PBS with 0.05% Tween-20 and 1% dry milk, were added. The plates were incubated for 2 hrs at 37 °C. The plates were then washed 3 times with PBS containing 0.05% Tween-20. Then, 100µl of O-phenylenediamine (0.4mg/ml in citrate phosphate buffer containing 0.015% hydrogen peroxide; Sigma Chemical Co. St Louis, MO), were added to each well, and the reaction was stopped by the addition of 2.5N HCl. After 15 minutes the optical density at 492nm (OD<sub>492</sub>) was measured using a EL308 ELISA reader (Bio-Tek Instruments, Winooski, VT). The titer expressed in OD<sub>492</sub> unit was calculated as a multiple of the dilution in the linear portion of the standard plot.

### Cytotoxicity Assays

Mouse LECs cultured for 1-4 days were used to study the cytotoxic potential of the Abs by the dye exclusion test. The LECs which were attached to the MULTIWELL™ tissue culture plates (Falcon, Franklin Lake, NJ) were incubated in DMEM containing Abs at various dilutions with or without guinea pig complement (Gibco-BRL; diluted 1/10) for 3 hrs. Two control experiments were done, one in DMEM, and the other in DMEM plus normal mouse serum at the concentration of 1/40. LECs were harvested after trypsinization and subjected to the Trypan blue dye exclusion test.

### Protein Isolation

Mouse LEC proteins were fractionated as described elsewhere (Ibaraki, I., et al., *Exp. Eye Res.*, 1997, 64:229-238). Synthetic peptides or Ags were purchased from a commercial source (Bio-Synthesis, Inc., Louisville, TX). Purification of immunoglobulins (IgG and IgM)

was conducted as described previously (Singh et al., *J. Immunol.* 155:993-999, 1997). The eluted IgG and IgM and FCS were heat treated at 56 °C for 30 min to inactivate residual complement.

#### 5 Protein Blot Analysis

Water soluble proteins were dissolved in SDS-PAGE sample buffer, separated on SDS-PAGE, and then blotted onto Immobilon™-P (Millipore Corp. Bedford, MA) (LeGendre, *Biotechniques*, 1990, 9:788-805). The filters were incubated overnight with Abs (dilution 1:10-1:10,000) and washed. The secondary Ab was goat anti-human, mouse or  
10 rabbit IgG labeled with horseradish peroxidase (dilution 1:5,000; Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD), and the color was developed with 0.01% hydrogen peroxide and 0.05% 3,3-diamino-benzidine-tetra hydrochloride (DAB; Bio-Rad Lab., Hercules, CA). Protein size markers were purchased from Bio-Rad Laboratories.

#### 15 Cell Proliferation and <sup>3</sup>H-Thymidine Uptake Assays

Assays for cell growth were performed as follows: Mouse LECs were seeded at a density of  $2 \times 10^4$  cells/well in 96 well micro plates. Cells were maintained in DMEM with 10% FCS. Human cataract sera at various concentrations were added in triplicated well. Non-cataractous sera served as controls. Plates were kept in an incubator maintained at 37°C and  
20 6% CO<sub>2</sub> for 12hrs. Cells were pulsed thereafter with <sup>3</sup>H-thymidine (1μCi/well, NEN) for 16 hrs. The radioactivity incorporated into the DNA was precipitated with 1% trichloroacetic acid (Mallinckrodt, Inc., Paris, KN), and counted in a liquid scintillation counter.

#### Immunohistochemistry

25 For immunochemistry, human or mouse LECs were cultured in DMEM as described above, dissociated with 0.05% trypsin, and then fixed with 4% paraformaldehyde in 0.01 M phosphate-buffered saline (PBS: pH 7.4) for 2 hrs. After washing three times in PBS, they were blocked with 10% goat serum in PBS for 1 hr, and incubated with rabbit anti-LEDGF Ab (1:100 dilution in PBS) for 12 hrs at 4 °C. After washing three times in PBS for a total of  
30 30 minutes, they were treated with goat anti-rabbit IgG and HRP (1:2,000 dilution in PBS; Kirkegaard & Perry Laboratories, Inc.,) for 1 hr. They were washed three times in PBS for a total of 45 min and then incubated with DAB for 5 min.

### Cataract Assessment in Patients

Type and severity of cataract were graded using the Lens Opacity Classification System (LOCS III) (Chylack et al., *Arch. Ophthalmol.*, 1993, 111, 831-836). A cataract was defined as present in our patients if the LOCS III NO score was >1.8 and/or the LOCS III C score was >0.2 in either or both eyes.

### Cell Culture Under Environmental Stress Conditions

Mouse LECs were grown as described earlier. Wild type LECs and LECs transformed with the appropriate expression vector (See later description) were cultured under stress conditions as follows: 50,000 cells of each cell type were cultured (in triplicate) on 24-well culture plates in 0.5 ml of DMEM with 10% FCS at 37°C. After the attachment of cells to the bottom of the well (16hrs), the cells were washed twice with DMEM and further cultured in 0.5 ml DMEM without serum at either 41°C (for hyperthermic stress) or 37°C with various concentration of H<sub>2</sub>O<sub>2</sub> (for hyper-oxidative stress). In the hyperthermic stress experiment, the cell viability was monitored at day 0, 1, 3, and 7, after trypsinization with 0.5 ml of trypsin-EDTA and 1 ml of trypan blue staining to evaluate cell death. In the hyper-oxidative stress experiment, the cells were monitored at 0, 2, 6, and 24 hrs after addition of H<sub>2</sub>O<sub>2</sub>. We calculated the percent of living cells from the ratio of the trypan blue unstained cell number to the total cell number.

### Cell Transformation with Fluorescent Fusion Mammalian Expression Vectors

A fluorescent fusion protein containing GFP-LEDGF was generated with the Living Colors™ system (Clontech, Palo Alto, CA). The LEDGF cDNA containing the entire coding region was subcloned just downstream of the GFP gene (gene construct; pEGFP-LEDGF, protein product; GFP-LEDGF). We also generated another construct having the 5'-end 1600 nucleotides (N-terminus 130 amino acid). The HindIII-BamHI LEDGF cDNA fragment was subcloned just downstream of GFP gene (gene construct; pEGFP-mutLEDGF, protein product; GFP-mutLEDGF). Each of these constructs generated approximately a 90 kDa fusion protein (GFP-LEDGF) and a 45 kDa fusion protein (GFP-mutLEDGF) respectively. Expression of these constructs was driven by the cytomegalovirus late promoter. Fluorescence photography was performed with an Eclipse E600 microscope (Nikon, Melville, NY).

### Trypan Blue Dye Exclusion Test

The LECs in the 24-well tissue culture plates were incubated for 1-3 days in DMEM, with or without 10% FCS and anti-LEDGF Abs (Dilution 1:100). The Abs to LEDGF were prepared in rabbit. Two sets of controls were used: one consisted of the standard DMEM and the second contained normal rabbit serum in DMEM. LECs were trypsinized after incubation with the Abs to LEDGF. We estimated the number of viable cells in each suspension with a trypan blue dye (0.4% in saline, Gibco-BRL/LTI, Rockville, MD) exclusion test, and calculated the percentage of damaged cells for each experiment.

### Example 1: Cloning of LEDGF cDNA and Northern Analysis

Using sera of ARC patients we identified a clone (HLC10) from a human LEC cDNA expression library. The serum contained an Ab which bound to a protein produced by HLC10. Sequence analysis of the full length cDNA (SEQ ID NO:1) revealed an open reading frame able to encode a protein of 530 amino acids (SEQ ID NO:2) with a predicted molecular mass of 61 kDa. A BLAST database search revealed homology to the hepatoma-derived growth factor (HDGF- SEQ ID NOs:14 and 15)(Nakamura et al., *J. Biol. Chem.* 269:25143-25149, 1994). We thus named this gene LEDGF for lens-epithelial cell derived growth factor. The highest sequence homology between LEDGF and HDGF was found at the N-terminus.

Although, no signal peptide was found in LEDGF, there were several functional consensus sequences, two nucleotide localization consensus sequences, several putative casein kinase II sites, an A-kinase site, and two putative glycation sites. Forty-two percent of the amino acid residues of LEDGF were charged residues - 24% negatively (aspartic acid and glutamic acid), and 18% positively (lysine, arginine, and histidine). The unusually high content of arginine and lysine suggests that this protein is unstable and susceptible to proteolytic cleavage. The secondary conformation of the molecule, predicted from its primary amino acid sequence, was predominantly  $\beta$ -sheets and turns according to the algorithm (Chou and Fasman, *Adv. Enzymol.* 47:45-148, 1978). The deduced amino acid sequence was validated by Ab binding studies. Using the deduced amino acid sequence of LEDGF as a guide, two oligopeptides were synthesized; one corresponding to the highly conserved site in the N-terminus (FFGTHETAFLGPKDIFPYSE; SEQ ID NO:4) and the second to a specific site in the C-terminus (LYNKFKNMFLVGEGDSVIT; SEQ ID NO:6). Abs to each peptide were then raised in rabbits. Both anti-LEDGF Abs (N-terminal and C-terminal) bound to a

protein with a molecular weight of 61 kDa in human and mouse LECs. In addition, both Abs bound to LEDGF expressed in an *E. coli* expression system (see below and Fig. 1B, lane D). From these studies, we concluded that the clone which we had isolated was encoded to a 61 kDa protein expressed in human LECs.

#### Example 2: Tissue Specificity of LEDGF

We wished to know also which cell types expressed LEDGF. Total mRNAs were extracted from various mouse tissues, and Northern blot analysis indicated that mRNA corresponding to LEDGF was present at high levels in liver, lymphocytes and LECs and at low levels in many other tissues. When the Northern blots were washed at low stringency (0.5 x SSC at 20 °C), we found two additional bands of molecular size 4.5 kbp and 2.7 kbp in the liver preparation. When washed at higher stringency (0.1 x SSC at 62 °C), however, these bands disappeared, and only a 3.4 kbp band remained. This result suggested that mRNAs similar to LEDGF mRNA must be present in liver.

Next we detected LEDGF in cultured mouse and human LECs. Using a preparation of total soluble proteins, protein blot analysis, an ELISA assay, and the two afore-mentioned Ab probes (Abs to the N-terminus and C-terminus of LEDGF), we determined ELISA titers of  $\geq 2,000$  OD<sub>492</sub> units for each anti-LEDGF Ab. These Abs bound specifically to a 61 kDa protein in cultured LECs. In addition, four smaller bands (50, 45, 32, and 20 kDa proteins) were present on the protein blots. We also looked for LEDGF in capsulotomy specimens obtained at routine surgery for ARC, and in contrast to the results with cultured LECs, we found multiple blurry bands near the 61 kDa protein and no binding to the four smaller bands (50, 45, 32, and 20 kDa proteins). These results suggested that the 61 kDa protein was full-sized LEDGF, and the three smaller bands were partially degraded products. The multiple blurry bands near the 61 kDa protein in the capsulotomy specimens may be post-translationally modified, but not degraded LEDGF (see below and Fig. 4, lane 8). In the protein blot of liver there was a major band with a molecular weight about 35 kDa which must be HDGF. HDGF should cross-react with Abs to the N-terminus, but not the C-terminus peptide of LEDGF. Proteins with molecular weights similar to HDGF were found in lymphocytes, spleen, and lung cells. In addition, several positive bands were found in proteins of other tissues. Further work will be needed to determine if these proteins are partially degraded LEDGF, a family of similar proteins, or another group of proteins.



### Example 3: Immunohistochemistry

Immunohistochemical staining for LEDGF on human LECs was carried out with light microscope and anti-LEDGF Abs (N-terminus) and horseradish peroxidase (HRP)-labeled secondary Abs. The entire cell surface was strongly stained with the Abs. The result suggested that LEDGF was bound to the cell surface of the LECs. Similarly, immunostaining of human LECs of capsulotomy specimens from cataract surgery exhibited strong positive staining.

### Example 4: LEDGF is a Phospho-Protein

We found several putative casein kinase II sites (see above) in LEDGF and also multiple blurry bands on the protein blot analysis of LEDGF from cultured LECs and from capsulotomy specimens. We speculated that LEDGF was a phosphorylated protein. We incubated mouse LECs which over-expressed LEDGF or the control LECs-vector (see below) with  $^{32}\text{P}$ -orthophosphate. Soluble proteins were immune-precipitated with anti-LEDGF Abs (mixture of N-terminal and C-terminal), the precipitated proteins were separated on SDS-PAGE and tested for radioisotope incorporation into LEDGF. As expected, the LEDGF (61 kDa-protein) was indeed phosphorylated (data not shown). Anti-LEDGF-Abs (mixture) preincubated with a mixture of N-terminal and C-terminal peptides did not precipitate 61 kDa phospho-protein (LEDGF).

### Example 5: Expression of LEDGF in an *E. coli* Expression System

LEDGF cDNA was introduced into the bacterial expression system, glutathione-S-transferase (GST) gene fusion system (pGEX-2T), to facilitate LEDGF expression. The entire coding sequence of the cDNA was subcloned into pGEX-2T vector using SmaI and EcoRI sites.

These expression systems produced very small amounts of full-size LEDGF. Since there was a highly GC rich sequence in the 5'-noncoding sequence of LEDGF mRNA, we removed the entire 5'-noncoding region by cutting at the BamHI site located just upstream of the initiation codon AUG. The LEDGF cDNA fragment was re-ligated directly under the GST. This construct produced a larger amount of a fusion protein (90 kDa) between GST(29 kDa), and LEDGF (61 kDa) in an *E. coli* strain (BL 21) (see Fig. 1B, lane D). We cleaved off GST molecule with thrombin protease, purified LEDGF, and used it for biological assays.

#### Example 6: LEDGF Stimulates Growth of LECs

To study the *in vitro* effects of LEDGF we expressed LEDGF in the *E. coli* expression system (pGEX-2T), and in mouse LECs. Various amounts of purified LEDGF (0.12-5 mg/ml) were added to the culture medium, and the growth of LECs was studied. Higher the concentrations of LEDGF (1-5mg/ml), stimulated LEC growth (<sup>3</sup>H-thymidine uptake) more, and lower concentrations (0.12-0.25mg), stimulated LEC growth less (Table I). Suboptimal concentration of LEDGF for mouse LECs were 1-5 mg/ml for 2 days culture and 0.5-1.0 mg/ml for 3 days culture.

#### Example 7: Cells Over-Expressing LEDGF Stimulate Growth

Mouse LECs and COS7 cells were transfected with the eukaryotic expression vector (pcDNA3) containing LEDGF cDNA. Cells were cultured in DMEM having 400 mg/ml of geneticin (a neomycin analog) for several weeks to establish a stable transfected cell line. The amount of LEDGF in transfected mouse LECs was more than 5-10 times higher than that in control cells (data not shown). Stable mouse LEC lines were established, then elicited ( $1 \times 10^5$  cells/tube), frozen, and stored at -70°C. These LECs are called "LECs-over expressing LEDGF", and the control LEC having an original vector are called "LECs-vector" in this paper.

After inoculation, LECs which overexpressed LEDGF attached themselves to the bottom of the culture plates much faster than those which expressed the LECs-vector. Growth of the LECs-over expressing LEDGF, as indicated by uptake of <sup>3</sup>H-thymidine, was also much faster than that of the LECs-vector (Table II). Also, attachment of cells to the bottom of the culture plate after inoculation was much faster in COS7 cells which expressed LEDGF than in the COS7 cells containing only the vector. Growth of the COS7 cells-over expressing LEDGF was three times faster than that of the COS7-vector.

Next, we wished to know whether LEDGF regulated synthesis of specific proteins in LECs. We cultured mouse LECs over-expressing LEDGF and LECs-vector with <sup>35</sup>S-methionine for 12 hrs. The soluble proteins were applied on the SDS-PAGE. The resulting autoradiogram indicated that synthesis of several (>7) proteins was stimulated in the LECs over-expressing LEDGF, and synthesis of two proteins was decreased (Fig. 1A). These results indicated that LEDGF regulates the synthesis and accumulation of several proteins in mouse LECs.

#### Example 8: LEDGF is Secreted into Culture Medium

We wished to know whether the LEDGF was secreted from LECs and released into the culture medium. The mouse LECs-over expressing LEDGF and LECs-vector were cultured in DMEM without FCS. Initially mouse LECs were cultured in normal DMEM with 10% FCS for 1 day; after 1 day most LECs were attached to the bottom of culture plate. Then the initial medium was discarded, and the LECs were washed in DMEM without FCS. The medium was changed again after 12 hr incubation; then cells were cultured continuously for the next 3 days in DMEM without FCS. The medium was collected and called "conditioned medium". Almost all of cells appeared normal, but mouse LECs did grow a little in DMEM without FCS. The medium was harvested and applied to a Centricon 30 (Bio-con) which removed molecules smaller than 30 kDa. Protein blot analysis using anti-LEDGF Abs (mixtures) revealed a band of immune-positive 61 kDa protein (LEDGF) (Fig. 1B). The yield of LEDGF from 50 ml of culture medium was approximately 0.6 mg/ $4 \times 10^6$  cells/3 days. The result suggested that LEDGF was a secretory protein released from LECs into the culture medium. Similarly, COS7 cells-over expressing LEDGF were cultured in DMEM for 3 days, and we collected similarly conditioned medium. The amount of LEDGF in the medium was less (02 mg/ $4 \times 10^6$  cells/3 days) than that in medium in which LECs had been cultured.

Next we examined the effect of conditioned medium obtained from COS7 cells over-expressing LEDGF on the growth of mouse LECs. The growth of cultured cells was stimulated 3-fold by the conditioned medium from COS7 cells-over expressing LEDGF compared to the conditioned medium from COS7 cells-vector. The latter did not stimulate LEC growth at all (Fig. 2). The stimulatory effect of the conditioned medium from COS7 cells-over expressing LEDGF was blocked by the addition of anti-LEDGF Abs. These results indicated that LEDGF from COS7 as well as LECs can stimulate LEC growth. Thus, we conclude that the LEDGF is a novel growth factor that is also secreted from various tissues.

#### Example 9: Anti-LEDGF Abs Killed LECs in Culture

We cultured mouse LECs in DMEM with 10% FCS to test whether anti-LEDGF Abs have an effect on the LECs. After two and half days of culture with the Abs,  $^3\text{H}$ -thymidine was added to the culture medium and the incubation continued for an additional 16 hrs. The cells were harvested, and radioisotope incorporation into DNA was investigated. Uptake of  $^3\text{H}$ -thymidine into LECs was inhibited significantly in the presence of anti-LEDGF Abs (1:10-

1:80 dilutions) (Fig. 3A). In contrast, <sup>3</sup>H-thymidine uptake in LECs cultured in the absence of the Abs was apparently stimulated. This result indicated that anti-LEDGF Abs strongly inhibited mitotic activity by the 3rd day in culture.

Next we studied morphological changes of LECs cultured with the Abs. Human LECs were cultured for 14 days with and without anti-LEDGF Ab (N-terminal) which had been purified by protein-A column chromatography. For the first 6 days LECs with and without Abs grew well, but, by the 7th day, a large numbers of cells incubated with anti-LEDGF Abs manifested damage, and by the 14th day most cells incubated with the Ab were dead and floated to the surface of the culture medium. The control cells incubated with serum collected from the rabbit before immunization with LEDGF, grew normally throughout the 14 day period (Fig. 3B).

Mouse LECs cultured in a similar fashion with and without anti-LEDGF Abs (C-terminal) or anti-LEDGF Abs (N-terminal) grew normally for 3 days, but by the 4-5th day, the cells cultured with either anti-LEDGF Ab (C-terminal and N-terminal) appeared damaged. By 7 days, most of them were dead. Mouse LECs, cultured with control serum (pre-bled rabbit sera), grew continuously for the next 10 days. These experiments suggested that anti-LEDGF Abs block the stimulatory effect on cell growth by LEDGF, and that without such LEDGF stimulation, cells die.

#### Example 10: High Levels of Anti-LEDGF Ab are present in Sera of Patients with ARC

Since the clone (HLC10) was identified with serum from a patient with ARC, we expected to find auto-Abs to LEDGF in human serum. To confirm this, we performed protein blot analyses with human LEC proteins and sera from patients with ARC (Fig. 4). One hundred forty seven out of 153 sera from ARC patients had auto-Abs to LEDGF. These sera were strongly growth inhibitory for LECs in culture as shown previously, (Singh et al., *Exp. Eye Res.* Submitted, 1997). Both IgG and IgM were found in most sera from ARC patients (Fig. 4) and IgM was more 19 times more cytotoxic than IgG on a per mg protein basis.

#### Example 11: Temperature Effect on LECs Over-expressing GFP-LEDGF

50,000 LECs were cultured on (triplicate) 24-well culture plates in 0.5 ml of DMEM containing 10% FCS and were incubated overnight at 37°C. Most cells were attached on the bottom of plates after 24 hrs. The cells were then washed twice with 0.5 ml

of DMEM without FCS and were kept in culture for additional 7 days at 41°C in the DMEM. The initial cell number/well on the plate was about the same between cells over-expressing LEDGF and the controls. After 1 day, LECs over-expressing LEDGF survived well (>78% cells) and grew further. By the 3rd day cell growth appeared to reach a plateau, and between days 3-7 cells did not grow but in their majority survived (83% at 3 days and 72% at 7 days) the serum free medium at 41°C. In contrast, control cells grew and survived well during the first 24 hrs (>80% survival), but gradually started dying after that (59% survival at 3 days and 39% survival at 7 days). These results show that LECs over-expressing LEDGF survive better under heat-stress.

#### Example 12: Expression of Specific Proteins in the Cells Over-expressing LEDGF

LECs over-expressing GFP-LEDGF and control LECs (transfected with vector alone-GFP plasmid) were cultured at 37°C for 2 days. Total cell homogenates from each cell type were prepared after the 2day culture. Equal amounts of proteins were separated on tan SDS-PAGE and blotted onto membrane filters for immunostaining with corresponding Abs. We quantified Heat Shock Proteins (HSPs) 100, 90, 70, 60, 27, and  $\alpha\beta$ -crystallin on the blot using antibody probes (Gibco-BRL). Although, HSP 60 was expressed at relatively high levels, it was not stimulated in LECs over-expressing LEDGF. We found between 10 and 5 times higher levels of HSP 27 and  $\alpha\beta$ -crystallin, respectively, in these cells over-expressing LEDGF than that in the control cells having vector alone. The rest of HSPs (100, 90, 70, and 32) were not expressed at a detectable level in LECs with or without over-expressing LEDGF.

#### Example 13: Oxidative Stress on LECs Over-expressing LEDGF

A well-studied environmental stress condition in the lens field is a oxidation. We investigated whether LECs resisted oxidative stress damage. The LECs were cultured in the DMEM with 10% FCS for 1 day as described above. Cells were then transferred into serum free DMEM in the presence of various amounts of  $H_2O_2$  (from 31  $\mu M$  to 250  $\mu M$ ). Growth and survival of LECs were monitored under the light microscope. The LECs over-expressing LEDGF grew and survived better than the cells being transfected with the vector alone. At 125 and 62.5  $\mu M$  of  $H_2O_2$ , the control cells were mostly dead after a 6 hour incubation, but the cells over-expressing LEDGF survived much better (>80% survival).

At 62.5  $\mu$ M of  $H_2O_2$ , control cells were mostly dead after a 24 hr incubation with the LECs over-expressing LEDGF surviving better (> 80% survival).

### Figure Legends

5 Figure 1. *In vitro* effects from LEDGF over-expression on LECs.

(A). Mouse LECs over-expressing LEDGF (lane B) and LECs-vector (lane A) were cultured for 2.5 days, then  $^{35}$ S-methionine was incorporated for 12 hrs. Protein synthesis of LECs over-expressing LEDGF was apparently altered. The synthesis of some proteins was stimulated (indicated by arrow in the right margin) and of others was inhibited (indicated by  
10 arrow in the left margin). Equal amounts of radioisotope was applied in these two samples. (B). LEDGF was found in culture medium. Mouse LECs-over expressing LEDGF or COS7-over expressing LEDGF were cultured in DMEM for 72 hrs, and LEDGF in the medium was analyzed by immunostaining with Abs to LEDGF. Lane A, Molecular size markers are the same as on Fig. 2B. Lane B, LEDGF in medium from cultured COS7 cells-over expressing  
15 LEDGF. Lane C, LEDGF in medium from cultured mouse LEC-over expressing LEDGF. Lane D, Expression of LEDGF in prokaryotic pGEX-2T expression vector system (*E. coli*, BL21). Fusion protein (100 kDa) between LEDGF and GST is indicated by an arrow head in the right margin. LEDGF is indicated by an arrow in the left margin.

20 Figure 2. Growth stimulating effects of LEDGF-conditioned medium on LECs.

Conditioned medium from COS7 cells over-expressing LEDGF stimulated  $^3$ H-thymidine uptake in mouse LECs. +LEDGF indicates that conditioned medium from COS7 cells over-expressing LEDGF. -LEDGF and DMEM indicate conditioned medium from COS7 vector-alone and medium only, respectively, showing no significant growth stimulation.

25 +LEDGF+Abs indicates that the conditioned medium from COS7 over-expressing LEDGF mixed with equal molar amounts of Abs to LEDGF. This preparation did not stimulate  $^3$ H-thymidine incorporation.

Figure 3. *In vitro* anti-LEDGF Ab effects on LECs.

30 (A). The Abs to LEDGF inhibited  $^3$ H-thymidine uptake in mouse LECs in culture. The LECs were cultured for 2.5 days with 1:10-1:80 dilutions of Ab to LEDGF, then  $^3$ H-thymidine was added, and further incubated an additional 16 hrs. The incorporated radioisotope (CPM) was

analyzed in a scintillation counter. The experiment was triplicated and presented as average CPMs.

(B). Human LECs killed by Abs to LEDGF. Human LECs were cultured +/- Abs to LEDGF. After 7 days in culture, the cell number decreased, and almost all LECs in cultures with Abs to LEDGF died. Control cultures without anti-LEDGF Abs grew normally.

Figure 4. Presence of anti-LEDGF Abs in sera of cataract patients.

Proteins obtained from human capsulotomy specimens were each blotted on 2 mm wide millipore filters, and each filter was stained with serum from individuals with ARC.

Approximately 1 mg/well of protein was analyzed, and each serum was diluted 1:20. An arrow indicates the 61 kDa region, and the nearby multiple fuzzy bands. Sera from 7 patients (numbered 1-7 at the top) are presented. The codes are for a second Ab or Ab mixture: goat anti-human IgA, IgG, or IgM. m: IgA+IgG+IgM mixture; G:IgG; M:IgM; S:size markers (108, 80, 51, 34, 27, and 16 kDa). Some sera have predominantly IgG and others have predominantly IgM. Lane 1 represents a patient with ARC had no detectable level of Ab to LEDGF, the rest of patients (lane 2-7) had the Abs. Lane 8 was presented as a reference. The same protein blot was stained with rabbit Abs to LEDGF (N-terminal, SEQ ID NO:4) and goat anti-rabbit IgG was used as a the second Ab. Note the fuzzy bands in the 61 kDa region (arrow). Approximately 1 µg/well of protein was analyzed with the human sera or Ab to LEDGF. Goat anti-human or anti-rabbit IgG were used as the second Abs.

Figure 5. A kit comprising an agent of the invention (e.g., anti-LEDGF Abs, LEDGF epitopes, etc.), a control agent, and instructions for utilizing such agents in diagnostic or therapeutic applications.

-54-

**Table I. Effect of recombinant LEDGF on  $^3\text{H}$ -thymidine uptake of LECs in culture**

| Incubation time (day) | <sup>3</sup> H-thymidine uptake (cpm) |         |          |         |         |         |         |
|-----------------------|---------------------------------------|---------|----------|---------|---------|---------|---------|
|                       | Concentration of LEDGF (mg/well)      | 5       | 1        | 0.5     | 0.25    | 0.12    | 0.00    |
| 2                     |                                       | 57,030± | 54,500±  | 53,000± | 38,900± | NA      | 34,000± |
|                       |                                       | 2,400   | 3,400    | 2,600   | 2,760   |         | 2,300   |
| 3                     |                                       | 74,700± | 101,950± | 97,400± | 90,300± | 85,200± | 47,400± |
|                       |                                       | 1,300   | 5,600    | 1,500   | 4,900   | 4,400   | 4,600   |

Equal numbers of mouse LECs ( $1 \times 10^5$  cells/well) were inoculated in the flat bottom microtiter plates and incubated for 2-3 days with 5, 1, 0.5, 0.25, 0.12 and 0.00 LEDGF. Three wells of mouse LECs were cultured for one experiment. The data represents an average of three experiments. Radioisotope was incorporated for 16 hours with 1  $\mu\text{Ci}$ /well of  $^3\text{H}$ -thymidine.

**Table II. Over expressed LEDGF stimulates  $^3\text{H}$ -thymidine uptake in mouse LECs**

| Incubation Time (day) | Mouse LECs with LEDGF pcDNA3 | Mouse LECs with Control |
|-----------------------|------------------------------|-------------------------|
| pcDNA3                |                              |                         |
| 1                     | 38,243 ± 1,873               | 7,694 ± 209             |
| 2                     | 110,671 ± 3,251              | 24,223 ± 2,449          |
| 3                     | 277,276 ± 26,324             | 47,909 ± 3,514          |
| 4                     | 213,754 ± 13,874             | 106,160 ± 8,383         |
| 5                     | 244,208 ± 14,252             | 103,810 ± 8,100         |
| 6                     | 74,812 ± 8,005               | 119,385 ± 8,310         |

Equal numbers of mouse LECs ( $1 \times 10^5$  cells/well) were inoculated in the flat bottom microtiter plates. Three wells of mouse LECs were cultured for each experiment. Data are an average of three experiments. Radioisotope was incorporated for 16 hours with 1  $\mu\text{Ci}$ /well of  $^3\text{H}$ -thymidine. Mouse LECs became confluent after 5 days in culture, and uptake of  $^3\text{H}$ -thymidine declined by 6 days.



Table III. Sequences with partial homologies to LEDGF

| Sequences with GenBank accession numbers: |   |
|---|---|
| 5   | U94319, U21717, Z78418, U58334, M21096, Z68750, X66367, M64437, AB014549, M73529, U48436, AF020200, Y07662, D82352, Z78205, U92436, X69910, AC004781, M24603, U56440, X02596, U62542, M95497, L16683, AJ002310, M95603, X94677, AF000993, AJ000109, AF012603, S37093, X76217, D83652, X66223, D86982, X54806, AL031031, M72711, U85962, U10564, M97563, S70397, AF039840, U59322, U92437, U97663, AB001835, S69350, U00674, U31809, M15025, Y00661, D83206, U63894, X56465, X66096, M64344, U91679, AF020199, M83298, X52828, U96180, M80550, AF000992, |
| 10  | AJ002308, L76569, U58678, U49791, U30246, U19759, , AA773624, AA521322, AA228130, AA772105, AA285372, N41025, W19666, AA937940, AA767142, N40993, N48306, N22081, D51131, AA679749, AA490641, AA115344, AA515178, AA227982, AA679542, N50725, AA639697, AA761805, AA906700, AA102786, AA322886, AA788615, C02698, C05293, H68589, H05226, AA456657, AA758913, D82424, N49031, AA648034, T24523, N47125, N64617, AA393305, AA861341, AA992385, AA389644,   |
| 15  | AA758341, N75869, R18910, AA626371, AA465159, AA368664, D81382, H86544, H84298, AA644639, AA877813, AA011028, AA056275, AA018441, N53694, AA020992, T83201, AA058563, AA047220, H86126, N41507, W20450, AA169778, AA731406, R38845, AA731403, AA770198, AA968479, R28454, R22429, D62104, AA250931, AA488229, H97847, AA283145, AA169696, H82607, AI041041, AA608413, AA867331, AA921107, AI048060, AA184165, AA039116, AA718349, AA542188, AA591351, AA177775,   |
| 20  | AA692690, AA146201, AA867019, AA792020, AA170751, AA693092, AA656644, AA636419, AA271872, AA146236, AA177309, AA623881, AA672210, AA940100, AA693167, AA681870, W83156, AA124286, AA547043, AA120067, AA647991, AA623726, AA014322, AA213040, AA511225, AA960457, AA213201, AA170671, AI035693, AA162694, AA444251, AA516678, AA023755, AA110235, AA407127, AA855403, AA050131, AA619989, AA073118, AA161809, AA222163, AA871188,   |
| 25  | AA792147, AA796131, AA110787, AA710005, AA710374, AA517361, AA537432, AA718233, AA870039, AA111345, W08033, AA260016, W99877, AA655390, D18351, AA072736, AA119746, AA407292, AA645669, AA674540, AA015354, W54255, AA106100, AA114708, AA546945, AA574627, AA756108, AA764184, Z74644, AA771131, AA013681, AA110312, AA686890, H34999, AA964144, AI045732, AA392351, C41181, D48746, AI011500, C41350, D67725, C40685, D74054, D74250, C45006,   |
| 30  | AA216474, H16500, R65140, D47814, W51610, AA728013, AA592046, AA294717, AA228197, AA257749, W51555, AA275402, AA791301, AA728017, AA273088, AA007746, AA542770, AA257821, AA294785, W69065, AA114525, AA241702, AA539267, R65141, AA216511, R65147, H21271, AA542704, N52099, AA728000, AA072531, AA294198, AA956969, AA964324, AA998070, AA955499, H74375, AA550426, AA858784, AA963079, D24013, AI011491, AI028970, AA859961, N97602,   |
| 35  | AA799748, AA817741, AA440741, AA944662, AI029487, C74424, AA965055, D23620, D16039, R86636, C26690, C73046, AA851680, AA851681, AA957337, D49269, AA957771, AA997712, AI029018, D24530, D24454, R90424, C11742, AI008716, AI012646, D24476, C19142, C19898, C74483, AA728663, AI030304, D23783.   |

All references disclosed herein are incorporated by reference in their entirety.

What is claimed is presented below and is followed by a Sequence Listing.

We claim:

**CLAIMS**

1. An isolated nucleic acid molecule, comprising
  - (a) nucleic acid molecules which hybridize under stringent conditions to a molecule consisting of a nucleic acid of SEQ ID NO:1 and which code for a Lens Epithelial Cell Derived Growth Factor polypeptide,
  - (b) deletions, additions and substitutions of (a) which code for a respective lens epithelial cell derived growth factor polypeptide,
  - (c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and
  - (d) complements of (a), (b) or (c).
2. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises SEQ ID NO:1.
3. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule is the nucleic acid molecule of SEQ ID NO:13 or a fragment thereof.
4. An isolated nucleic acid molecule selected from the group consisting of
  - (a) a fragment of a nucleic acid molecule of SEQ ID NO:1, of sufficient length to represent a sequence unique within the human genome, and identifying a nucleic acid encoding a Lens Epithelial Cell Derived Growth Factor polypeptide,
  - (b) complements of (a),provided that the fragment includes a sequence of contiguous nucleotides which is not identical to any sequence selected from the sequence group consisting of
  - (1) sequences having the GenBank accession numbers of Table III,
  - (2) complements of (1), and
  - (3) fragments of (1) and (2).
5. The isolated nucleic acid molecule of claim 4, wherein the sequence of contiguous nucleotides is selected from the group consisting of:
  - (1) at least two contiguous nucleotides nonidentical to the sequence group,
  - (2) at least three contiguous nucleotides nonidentical to the sequence group,

- (3) at least four contiguous nucleotides nonidentical to the sequence group,
- (4) at least five contiguous nucleotides nonidentical to the sequence group,
- (5) at least six contiguous nucleotides nonidentical to the sequence group,
- (6) at least seven contiguous nucleotides nonidentical to the sequence group.

5

6. The isolated nucleic acid molecule of claim 4, wherein the fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20, nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides, and 200 nucleotides.

10

7. The isolated nucleic acid molecule of claim 4, wherein the molecule encodes a polypeptide, or a fragment of, which binds a human antibody.

15

8. An expression vector comprising the isolated nucleic acid molecule of claims 1, 2, 3, 4, 5, 6, or 7 operably linked to a promoter.

9. An expression vector comprising the isolated nucleic acid molecule of claim 4 operably linked to a promoter.

20

10. A host cell transformed or transfected with the expression vector of claim 8.

11. A host cell transformed or transfected with the expression vector of claim 9.

25

12. An isolated polypeptide encoded by the isolated nucleic acid molecule of claim 1, 2, or 3, wherein the polypeptide, or fragment of the polypeptide, has protein synthesis induction activity.

30

13. The isolated polypeptide of claim 12, wherein the isolated polypeptide is a secreted protein encoded by the isolated nucleic acid molecule of claim 2.

14. The isolated polypeptide of claim 13, wherein the isolated polypeptide comprises a

polypeptide having the sequence of amino acids 1-530 of SEQ ID NO:2.

15. An isolated polypeptide encoded by the isolated nucleic acid molecule of claim 1, 2, or 3, wherein the polypeptide, or fragment of the polypeptide, is immunogenic.

5

16. The fragment of claim 15, wherein the fragment, or portion of the fragment, binds a human antibody.

10

17. An isolated polypeptide which binds selectively a polypeptide encoded by the isolated nucleic acid molecule of claim 1, 2 or 3.

18. The isolated polypeptide of claim 17, wherein the isolated polypeptide binds to a polypeptide having the sequence of amino acids of SEQ ID NO:2.

15

19. The isolated polypeptide of claim 17, wherein the isolated polypeptide binds to a polypeptide selected from the group consisting of a polypeptide having the sequence of amino acids of SEQ ID NO:4, a polypeptide having the sequence of amino acids of SEQ ID NO:6, and a polypeptide having the sequence of amino acids of SEQ ID NO:8.

20

20. The isolated polypeptide of claim 17, wherein the isolated polypeptide binds to a polypeptide having the sequence of amino acids of SEQ ID NO:2.

25

21. The isolated polypeptide of claim 20, wherein the isolated polypeptide is an antibody or an antibody fragment selected from the group consisting of a Fab fragment, a F(ab)<sub>2</sub> fragment or a fragment including a CDR3 region selective for the polypeptide having the sequence of amino acids of SEQ ID NO:2.

30

22. An isolated polypeptide comprising a fragment of the polypeptide of claim 12 of sufficient length to represent a sequence unique within the human genome and identifying a polypeptide that has protein synthesis induction activity, provided that the fragment includes a sequence of contiguous amino acids which is not identical to any sequence selected from the sequence group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID

NO:12, and SEQ ID NO:22.

23. A method for determining an individual's susceptibility to developing cataracts, comprising:

- 5           a) obtaining a test sample from the individual containing antibodies,  
          b) measuring the level of anti-LEDGF antibodies in the test sample,  
          c) comparing the level of anti-LEDGF antibodies in the test sample to a control,  
wherein the level of anti-LEDGF antibodies compared to the control is indicative of the  
individual's susceptibility to developing cataracts.

10

24. The method of claim 23, wherein the test sample is blood.

25. The method of claim 23, wherein the test sample is tissue selected from the group  
consisting of epidermis and buccal scrapings.

15

26. A kit, comprising a package containing:

an agent that selectively binds to the isolated nucleic acid of claim 1 or an expression  
product thereof, and

20           a control for comparing to a measured value of binding of said agent to said isolated  
nucleic acid of claim 1 or expression product thereof.

27. The kit of claim 26, wherein the control is a predetermined value for comparing to the  
measured value.

25           28. The kit of claim 26, wherein the control comprises an epitope of the expression  
product of the nucleic acid of claim 1.

29. A kit, comprising a package containing:

30           an epitope that selectively binds to an anti-LEDGF antibody, and  
          a control for comparing to a measured value of binding of said epitope to said anti-  
LEDGF antibody.

30. The kit of claim 29, wherein the epitope is SEQ ID NO:2 or an anti-LEDGF antibody binding fragment thereof, and wherein said control is a predetermined value.

31. A method for treating a subject with an elevated level of anti-LEDGF antibodies to inhibit the development of cataracts, comprising:

administering to a subject in need of such treatment a polypeptide of claim 12 in an amount effective to suppress the level of anti-LEDGF antibodies in the subject, thereby inhibiting the formation of opacities in a crystalline lens of the subject.

32. The method of claim 31, wherein the polypeptide of claim 12 is administered orally.

33. The method of claim 31, wherein the polypeptide of claim 12 is administered intravenously.

34. The method of claim 31, wherein the polypeptide of claim 12 is administered through a nasal spray.

35. A method for determining the level of LEDGF expression in a subject, comprising:

- a) obtaining a test sample from the individual,
- b) measuring the expression of LEDGF in the test sample,
- c) comparing the measured expression of LEDGF to a control.

36. The method of claim 35, wherein the expression of LEDGF in (b) is LEDGF mRNA expression.

37. The method of claim 35, wherein the expression of LEDGF in (b) is LEDGF polypeptide expression.

38. The method of claim 35, wherein the test sample is tissue.

39. The method of claim 35, wherein the test sample is a biological fluid.

40. The method of claim 36, wherein LEDGF mRNA expression is measured using the Polymerase Chain Reaction (PCR).
41. The method of claim 36, wherein LEDGF mRNA expression is measured using  
5 northern blotting.
42. The method of claim 37, wherein LEDGF polypeptide expression is measured using monoclonal antisera to LEDGF.
43. The method of claim 37, wherein LEDGF polypeptide expression is characterized  
10 using polyclonal antisera to LEDGF.
44. A method for treating a subject with a cancer expressing LEDGF, comprising:  
administering to a subject in need of such treatment an agent that selectively binds to  
15 an isolated nucleic acid molecule of claim 1 or an expression product thereof, in an amount effective to decrease LEDGF activity in the cancer and inhibit the proliferation of the cancer.
45. The method of claim 44, wherein the agent is an antisense nucleic acid.
46. The method of claim 44, wherein the agent is an isolated polypeptide.  
20
47. A pharmaceutical composition comprising:  
a pharmaceutically effective amount of an agent comprising of an isolated nucleic  
acid molecule of claim 1 or an expression product thereof, and  
25 a pharmaceutically acceptable carrier.
48. The pharmaceutical composition of claim 47 wherein the agent is an expression product of the isolated nucleic acid molecule of claim 1.
49. A method for decreasing LEDGF mediated activity in a subject, comprising:  
30 administering to a subject in need of such treatment an agent that selectively binds to an isolated nucleic acid molecule of claim 1 or an expression product thereof, in an amount



effective to decrease LEDGF mediated activity in the subject.

50. The method of claim 49, wherein the agent is an antisense nucleic acid.

5 51. The method of claim 49, wherein the agent is an isolated polypeptide.

52. A method for inducing cell-death in a cell, comprising:

10 contacting the cell with an agent that selectively binds to an isolated nucleic acid molecule of claim 1 or an expression product thereof, in an amount effective to decrease LEDGF mediated activity in the cell and to induce cell-death .

53. The method of claim 52, wherein the agent is an antisense nucleic acid.

54. The method of claim 52, wherein the agent is an isolated polypeptide.

15

55. A method for inhibiting differentiation of a cell *in vitro*, comprising:

contacting a cell *in vitro* with an agent that selectively binds to an isolated nucleic acid molecule of claim 1 or an expression product thereof, in an amount effective to decrease LEDGF mediated activity in the cell and inhibit differentiation of the cell.

20

56. The method of claim 55, wherein the agent is an antisense nucleic acid.

57. The method of claim 55, wherein the agent is an isolated polypeptide.

25

58. A method for increasing cell proliferation, comprising:

contacting a cell expressing a LEDGF receptor with an agent that increases LEDGF stimulated cell proliferation in an amount effective to stimulate cell proliferation.

30

59. The method of claim 58, wherein the agent is a polypeptide encoded by the nucleic acid of SEQ ID NO:1.

60. The method of claim 58, wherein the agent is a polypeptide having the amino acid

sequence of SEQ ID NO:2, or a LEDGF receptor stimulatory fragment thereof.

5 61. A method for promoting wound healing in a subject, comprising:  
administering to a subject in need of such treatment an agent that increases LEDGF stimulated  
cell proliferation, in an amount effective to promote wound healing in the subject.

62. The method of claim 61, wherein the agent is a polypeptide encoded by the nucleic  
acid of SEQ ID NO:1.

10 63. The method of claim 61, wherein the agent is a polypeptide having the amino acid  
sequence of SEQ ID NO:2, or a LEDGF receptor stimulatory fragment thereof.

15 64. A method for inhibiting environmental stress-induced cell-death, comprising:  
contacting a cell expressing a LEDGF receptor, under environmental stress  
otherwise sufficient to induce cell-death, with an agent that increases LEDGF mediated  
activity in an amount sufficient to inhibit death of said cell which otherwise would result from  
said environmental stress.

20 65. The method of claim 64, wherein the cell contacted forms part of a tissue.

66. The method of claim 64, wherein the cell contact occurs *in vitro*.

25 67. The method of claim 64, wherein the environmental stress is selected from the group  
consisting of: physical trauma, oxidative stress, chemical stress, and UV irradiation.

68. The method of claim 64, wherein the agent is a polypeptide encoded by the nucleic  
acid of SEQ ID NO:1.

30 69. The method of claim 64, wherein the agent is a polypeptide having the amino acid  
sequence of SEQ ID NO:2, or an LEDGF receptor stimulatory fragment thereof.

70. A method for increasing heat-shock protein activity in a cell, comprising:

contacting the cell with an isolated nucleic acid molecule of claim 1 or an expression product thereof, in an amount effective to increase LEDGF mediated activity in the cell and to increase heat-shock protein activity in the cell.

5        71.    The method of claim 70, wherein the cell contacted forms part of a tissue.

72.    The method of claim 70, wherein the cell contact occurs *in vitro*.

10       73.    The method of claim 70, wherein the expression product is a polypeptide encoded by the nucleic acid of SEQ ID NO:1.

15




Fig. 1A



Fig. 1B

2/4




Fig. 2A




Fig. 2B

3/4




Fig. 3




Fig. 5




Fig. 4

## SEQUENCE LISTING

&lt;110&gt; Brigham &amp; Women's Hospital, Inc.

<120> Lens Epithelial Cell Derived Growth  
Factor

&lt;130&gt; B0801/7079WO

&lt;140&gt; Unknown

&lt;141&gt; 1998-07-23

&lt;150&gt; U.S. 60/053,549

&lt;151&gt; 1997-07-23

&lt;160&gt; 22

&lt;170&gt; FastSEQ for Windows Version 3.0

&lt;210&gt; 1

&lt;211&gt; 3360

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (311)...(1900)

&lt;400&gt; 1

```

gggagccgcg cgaggagcagc gcagctacgg cggcggcagc ggcggcgcggt ttgcgattcc      60
gagccgttga gacgcctctg cggcagctgg tggcgaggt ggcttgctg gacgcgggta      120
gaggcgaccg gccagcaacc gcagcgtcgg cgcccgcggc ccgggcagca ggcgcgtcgg      180
gagcccccga ggcatacctcc ccgccccgcg ggccccggtag ctggggccgc gtcgcgcgcc      240
cgcatccccg cgccgcgcga tctcctcgcc gcctcccggtg cttcggaccc ccggtctcgc      300
ccccggaaac atg act cgc gat ttc aaa cct gga gac ctc atc ttc gcc      349
              Met Thr Arg Asp Phe Lys Pro Gly Asp Leu Ile Phe Ala
                1              5              10

aag atg aaa ggt tat ccc cat tgg cca gct cga gta gac gaa gtt cct      397
Lys Met Lys Gly Tyr Pro His Trp Pro Ala Arg Val Asp Glu Val Pro
    15              20              25

gat gga gct gta aag cca ccc aca aac aaa cta ccc att ttc ttt ttt      445
Asp Gly Ala Val Lys Pro Pro Thr Asn Lys Leu Pro Ile Phe Phe Phe
    30              35              40              45

gga act cat gag act gct ttt tta gga cca aag gat ata ttt cct tac      493
Gly Thr His Glu Thr Ala Phe Leu Gly Pro Lys Asp Ile Phe Pro Tyr
    50              55              60

tca gaa aat aag gaa aag tat ggc aaa cca aat aaa aga aaa ggt ttt      541
Ser Glu Asn Lys Lys Glu Lys Tyr Gly Lys Pro Asn Lys Arg Lys Gly Phe
    65              70              75

```



|   |      |
|---|------|
| aat gaa ggt tta tgg gag ata gat aac aat cca aaa gtg aaa ttt tca | 589  |
| Asn Glu Gly Leu Trp Glu Ile Asp Asn Asn Pro Lys Val Lys Phe Ser |      |
| 80 85 90  |      |
| agt caa cag gca gca act aaa caa tca aat gca tca tct gat gtt gaa | 637  |
| Ser Gln Gln Ala Ala Thr Lys Gln Ser Asn Ala Ser Ser Asp Val Glu |      |
| 95 100 105  |      |
| gtt gaa gaa aag gaa act agt gtt tca aag gaa gat acc gac cat gaa | 685  |
| Val Glu Glu Lys Glu Thr Ser Val Ser Lys Glu Asp Thr Asp His Glu |      |
| 110 115 120 125   |      |
| gaa aaa gcc agc aat gag gat gtg act aaa gca gtt gac ata act act | 733  |
| Glu Lys Ala Ser Asn Glu Asp Val Thr Lys Ala Val Asp Ile Thr Thr |      |
| 130 135 140   |      |
| cca aaa gct gcc aga agg ggg aga aag aga aag gca gaa aaa caa gta | 781  |
| Pro Lys Ala Ala Arg Arg Gly Arg Lys Arg Lys Ala Glu Lys Gln Val |      |
| 145 150 155   |      |
| gaa act gag gag gca gga gta gtg aca aca gca aca gca tct gtt aat | 829  |
| Glu Thr Glu Glu Ala Gly Val Val Thr Thr Ala Thr Ala Ser Val Asn |      |
| 160 165 170   |      |
| cta aaa gtg agt cct aaa aga gga cga cct gca gct aca gaa gtc aag | 877  |
| Leu Lys Val Ser Pro Lys Arg Gly Arg Pro Ala Ala Thr Glu Val Lys |      |
| 175 180 185   |      |
| att cca aaa cca aga ggc aga ccc aaa atg gta aaa cag ccc tgt cct | 925  |
| Ile Pro Lys Pro Arg Gly Arg Pro Lys Met Val Lys Gln Pro Cys Pro |      |
| 190 195 200 205   |      |
| tca gag agt gac atc att act gaa gag gac aaa agt aag aaa aag ggg | 973  |
| Ser Glu Ser Asp Ile Ile Thr Glu Glu Asp Lys Ser Lys Lys Gly Gly |      |
| 210 215 220   |      |
| caa gag gaa aaa caa cct aaa aag cag cct aag aag gat gaa gag ggc | 1021 |
| Gln Glu Glu Lys Gln Pro Lys Lys Gln Pro Lys Lys Asp Glu Glu Gly |      |
| 225 230 235   |      |
| cag aag gaa gaa gat aag cca aga aaa gag ccg gat aaa aaa gag ggg | 1069 |
| Gln Lys Glu Glu Asp Lys Pro Arg Lys Glu Pro Asp Lys Lys Glu Gly |      |
| 240 245 250   |      |
| aag aaa gaa gtt gaa tca aaa agg aaa aat tta gct aaa aca ggg gtt | 1117 |
| Lys Lys Glu Val Glu Ser Lys Arg Lys Asn Leu Ala Lys Thr Gly Val |      |
| 255 260 265   |      |
| act tca acc tcc gat tct gaa gaa gaa gga gat gat caa gaa ggt gaa | 1165 |
| Thr Ser Thr Ser Asp Ser Glu Glu Glu Gly Asp Asp Gln Glu Gly Glu |      |
| 270 275 280 285   |      |
| aag aag aga aaa ggt ggg agg aac ttt cag act gct cac aga agg aat | 1213 |
| Lys Lys Arg Lys Gly Gly Arg Asn Phe Gln Thr Ala His Arg Arg Asn |      |

| 290   | 295 | 300 |      |
|---|-----|-----|------|
| atg ctg aaa ggc caa cat gag aaa gaa gca gca gat cga aaa cgc aag<br>Met Leu Lys Gly Gln His Glu Lys Glu Ala Ala Asp Arg Lys Arg Lys<br>305 310 315     |     |     | 1261 |
| caa gag gaa caa atg gaa act gag cag cag aat aaa gat gaa gga aag<br>Gln Glu Glu Gln Met Glu Thr Glu Gln Gln Asn Lys Asp Glu Gly Lys<br>320 325 330     |     |     | 1309 |
| aag cca gaa gtt aag aaa gtg gag aag aag cga gaa aca tca atg gat<br>Lys Pro Glu Val Lys Lys Val Glu Lys Lys Arg Glu Thr Ser Met Asp<br>335 340 345     |     |     | 1357 |
| tct cga ctt caa agg ata cat gct gag att aaa aat tca ctc aaa att<br>Ser Arg Leu Gln Arg Ile His Ala Glu Ile Lys Asn Ser Leu Lys Ile<br>350 355 360 365 |     |     | 1405 |
| gat aat ctt gat gtg aac aga tgc att gag gcc ttg gat gaa ctt gct<br>Asp Asn Leu Asp Val Asn Arg Cys Ile Glu Ala Leu Asp Glu Leu Ala<br>370 375 380     |     |     | 1453 |
| tca ctt cag gtc aca atg caa caa gct cag aaa cac aca gag atg att<br>Ser Leu Gln Val Thr Met Gln Gln Ala Gln Lys His Thr Glu Met Ile<br>385 390 395     |     |     | 1501 |
| act aca ctg aaa aaa ata cgg cga ttc aaa gtt agt cag gta atc atg<br>Thr Thr Leu Lys Lys Ile Arg Arg Phe Lys Val Ser Gln Val Ile Met<br>400 405 410     |     |     | 1549 |
| gaa aag tct aca atg ttg tat aac aag ttt aag aac atg ttc ttg gtt<br>Glu Lys Ser Thr Met Leu Tyr Asn Lys Phe Lys Asn Met Phe Leu Val<br>415 420 425     |     |     | 1597 |
| ggt gaa gga gat tcc gtg atc acc caa gtg ctg aat aaa tct ctt gct<br>Gly Glu Gly Asp Ser Val Ile Thr Gln Val Leu Asn Lys Ser Leu Ala<br>430 435 440 445 |     |     | 1645 |
| gaa caa aga cag cat gag gaa gcg aat aaa acc aaa gat caa ggg aag<br>Glu Gln Arg Gln His Glu Glu Ala Asn Lys Thr Lys Asp Gln Gly Lys<br>450 455 460     |     |     | 1693 |
| aaa ggg cca aac aaa aag cta gag aag gaa caa aca ggg tca aag act<br>Lys Gly Pro Asn Lys Lys Leu Glu Lys Glu Gln Thr Gly Ser Lys Thr<br>465 470 475     |     |     | 1741 |
| cta aat gga gga tct gat gct caa gat ggt aat cag cca caa cat aac<br>Leu Asn Gly Gly Ser Asp Ala Gln Asp Gly Asn Gln Pro Gln His Asn<br>480 485 490     |     |     | 1789 |
| ggg gag agc aat gaa gac agc aaa gac aac cat gaa gcc agc acg aag<br>Gly Glu Ser Asn Glu Asp Ser Lys Asp Asn His Glu Ala Ser Thr Lys<br>495 500 505     |     |     | 1837 |
| aaa aag cca tcc agt gaa gag aga gag act gaa ata tct ctg aag gat   |     |     | 1885 |

Lys Lys Pro Ser Ser Glu Glu Arg Glu Thr Glu Ile Ser Leu Lys Asp  
 510 515 520 525

tct aca cta gat aac taggttgaca tacctggaat atagagaaca cttgagaagt 1940  
 Ser Thr Leu Asp Asn  
 530

ttgtaatggt tttcatttga aatagactgc tggaagttaa aattttttata agcataggtt 2000  
 tgatgttgaa aacttggttt gagggagaaa atccctttgt tttaaagtaa agtaaacatt 2060  
 atcgctaagt gtaacttggt cagtattaac agctacatta tacagtaaat gtgggataaa 2120  
 atccatttag aaaatgttaa actgcttttc cagacatggt ttagcatat tttcaattag 2180  
 tgtgtgtatg ttaatgtgta attgatagta gaacaaagtt acatttttaa aactgctact 2240  
 tgtataaacc ttgctcttt tcccaaatac tgtgggtttt gtgcatagtt tttacaaacc 2300  
 ttggatttac cagactgtct tttcactggt tgtgggtttt gtagaagtta cacattttta 2360  
 ttgtagataa aatgttactt ctatacaagt actcactccc tttttatcaa aagttaattt 2420  
 taatctcaca gtctacattg tgctacatta tccagcttct ttggaacaat gtgtgctctg 2480  
 tatgggtttt ttgggtatga caactaatta agcaactgac attgaactga gaattctaca 2540  
 aactataaaa cattaatttt tgaaggtaaat ttagttttgt ggctgggcat tcagtgaagt 2600  
 cttaggactt ctttgcagac aactgactgg gtatatatag gaatgaatct ggcttttaggg 2660  
 ttaaatcatt taaggctcct ttataggcag gcactagtaa ctaaaactga aaactaagta 2720  
 agtttatttt tgaggaatgt tgttaaaaaat gtcttttagga agtcactaaa acttaattgg 2780  
 aagaaaaaat catgatgctt atacaataaa tatgaataaa tgttatataa ggaaactcac 2840  
 ctatttgaaa tcatggetat attgttttta ttttctagat tccaaaaata caaacactag 2900  
 ttgttcagc attgtacttt gataagtctg tacattgacg tgtatggact aaatccaggg 2960  
 taaaatcaat gttacaaaat ttaaggggtat gttactaaa ggatagcatt tctaagatat 3020  
 ttggaatatt agggtcattt ggcacttctc agcaagtagg atacttctca tgtttttgaa 3080  
 attatatgaa tatggaaaaa aatggcttaa gaccagcgtc tctgtatgac attgtgtggt 3140  
 tgacctctg agataactgt tttcatctac agaattgcat ttttgctttt aaagaggtct 3200  
 tataatggaa ctaggaatca ccgttttgag agaacctgca tatataccag tcattatctg 3260  
 tttggtcctt atacagtttt aacttactta gatttattct agttaagcca taagttcaac 3320  
 gtgtaaactt gtttcatta aagaattttt ctatcaaaaa 3360

<210> 2

<211> 530

<212> PRT

<213> Homo Sapiens

<400> 2

Met Thr Arg Asp Phe Lys Pro Gly Asp Leu Ile Phe Ala Lys Met Lys  
 1 5 10 15  
 Gly Tyr Pro His Trp Pro Ala Arg Val Asp Glu Val Pro Asp Gly Ala  
 20 25 30  
 Val Lys Pro Pro Thr Asn Lys Leu Pro Ile Phe Phe Phe Gly Thr His  
 35 40 45  
 Glu Thr Ala Phe Leu Gly Pro Lys Asp Ile Phe Pro Tyr Ser Glu Asn  
 50 55 60  
 Lys Glu Lys Tyr Gly Lys Pro Asn Lys Arg Lys Gly Phe Asn Glu Gly  
 65 70 75 80  
 Leu Trp Glu Ile Asp Asn Asn Pro Lys Val Lys Phe Ser Ser Gln Gln  
 85 90 95  
 Ala Ala Thr Lys Gln Ser Asn Ala Ser Ser Asp Val Glu Val Glu Glu  
 100 105 110  
 Lys Glu Thr Ser Val Ser Lys Glu Asp Thr Asp His Glu Glu Lys Ala  
 115 120 125  
 Ser Asn Glu Asp Val Thr Lys Ala Val Asp Ile Thr Thr Pro Lys Ala

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 130 | Ala | Arg | Arg | Gly | Arg | Lys | Arg | Lys | Ala | Glu | Lys | Gln | Val | Glu | Thr | Glu |
| 145 | Glu | Ala | Gly | Val | Val | Thr | Thr | Ala | Thr | Ala | Ser | Val | Asn | Leu | Lys | Val |
|     | Ser | Pro | Lys | Arg | Gly | Arg | Pro | Ala | Ala | Thr | Glu | Val | Lys | Ile | Pro | Lys |
|     | Pro | Arg | Gly | Arg | Pro | Lys | Met | Val | Lys | Gln | Pro | Cys | Pro | Ser | Glu | Ser |
|     | Asp | Ile | Ile | Thr | Glu | Glu | Asp | Lys | Ser | Lys | Lys | Lys | Gly | Gln | Glu | Glu |
|     | Lys | Gln | Pro | Lys | Lys | Gln | Pro | Lys | Lys | Asp | Glu | Glu | Gly | Gln | Lys | Glu |
|     | Glu | Asp | Lys | Pro | Arg | Lys | Glu | Pro | Asp | Lys | Lys | Glu | Gly | Lys | Lys | Glu |
|     | Val | Glu | Ser | Lys | Arg | Lys | Asn | Leu | Ala | Lys | Thr | Gly | Val | Thr | Ser | Thr |
|     | Ser | Asp | Ser | Glu | Glu | Glu | Gly | Asp | Gln | Glu | Gly | Glu | Lys | Lys | Arg |     |
|     | Lys | Gly | Gly | Arg | Asn | Phe | Gln | Thr | Ala | His | Arg | Arg | Asn | Met | Leu | Lys |
|     | Gly | Gln | His | Glu | Lys | Glu | Ala | Ala | Asp | Arg | Lys | Arg | Lys | Gln | Glu | Glu |
|     | Gln | Met | Glu | Thr | Glu | Gln | Gln | Asn | Lys | Asp | Glu | Gly | Lys | Lys | Pro | Glu |
|     | Val | Lys | Lys | Val | Glu | Lys | Lys | Arg | Glu | Thr | Ser | Met | Asp | Ser | Arg | Leu |
|     | Gln | Arg | Ile | His | Ala | Glu | Ile | Lys | Asn | Ser | Leu | Lys | Ile | Asp | Asn | Leu |
|     | Asp | Val | Asn | Arg | Cys | Ile | Glu | Ala | Leu | Asp | Glu | Leu | Ala | Ser | Leu | Gln |
|     | Val | Thr | Met | Gln | Gln | Ala | Gln | Lys | His | Thr | Glu | Met | Ile | Thr | Thr | Leu |
|     | Lys | Lys | Ile | Arg | Arg | Phe | Lys | Val | Ser | Gln | Val | Ile | Met | Glu | Lys | Ser |
|     | Thr | Met | Leu | Tyr | Asn | Lys | Phe | Lys | Asn | Met | Phe | Leu | Val | Gly | Glu | Gly |
|     | Asp | Ser | Val | Ile | Thr | Gln | Val | Leu | Asn | Lys | Ser | Leu | Ala | Glu | Gln | Arg |
|     | Gln | His | Glu | Glu | Ala | Asn | Lys | Thr | Lys | Asp | Gln | Gly | Lys | Lys | Gly | Pro |
|     | Asn | Lys | Lys | Leu | Glu | Lys | Glu | Gln | Thr | Gly | Ser | Lys | Thr | Leu | Asn | Gly |
|     | Gly | Ser | Asp | Ala | Gln | Asp | Gly | Asn | Gln | Pro | Gln | His | Asn | Gly | Glu | Ser |
|     | Asn | Glu | Asp | Ser | Lys | Asp | Asn | His | Glu | Ala | Ser | Thr | Lys | Lys | Lys | Pro |
|     | Ser | Ser | Glu | Glu | Arg | Glu | Thr | Glu | Ile | Ser | Leu | Lys | Asp | Ser | Thr | Leu |
|     | Asp | Asn |     |     |     |     |     |     |     |     |     |     |     |     |     |     |

<210> 3  
 <211> 57  
 <212> DNA

**<220>**

<222> (1) ... (57)

ttt ttt gga act cat gag act gct ttt tta gga cca aag gat ata ttt 48  
Phe Phe Gly Thr His Glu Thr Ala Phe Leu Gly Pro Lys Asp Ile Phe  
1 5 10 15

cct tac tca 57  
Pro Tyr Ser

<210> 4

<211> 19

<212> PRT

<213> Homo Sapiens

<400> 4

Phe Phe Gly Thr His Glu Thr Ala Phe Leu Gly Pro Lys Asp Ile Phe  
1 5 10 15  
Pro Tyr Ser

<210> 5

<211> 54

<212> DNA

<213> Homo Sapiens

**<220>**

<221> CDS

<222> (1) ... (54)

<400> 5

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|
| tat | aac | aag | ttt | aag | aac | atg | ttc | ttg | ggt | ggt | gaa | gga | gat | tcc | gtg | 48 |
| Tyr | Asn | Lys | Phe | Lys | Asn | Met | Phe | Leu | Val | Gly | Glu | Gly | Asp | Ser | Val |    |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |    |

atc acc  
ile Thr

**<210> 6**

<211> 18

<212> PRT

<213> Homo Sapiens

<220>

&lt;221&gt; PEPTIDE

<222> (1) ... (18)

&lt;400&gt; 6

Tyr Asn Lys Phe Lys Asn Met Phe Leu Val Gly Glu Gly Asp Ser Val  
 1 5 10 15  
 Ile Thr

&lt;210&gt; 7

&lt;211&gt; 1017

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(1017)

&lt;400&gt; 7

aaa cca aga ggc aga ccc aaa atg gta aaa cag ccc tgt cct tca gag 48  
 Lys Pro Arg Gly Arg Pro Lys Met Val Lys Gln Pro Cys Pro Ser Glu  
 1 5 10 15

agt gac atc att act gaa gag gac aaa agt aag aaa aag ggg caa gag 96  
 Ser Asp Ile Ile Thr Glu Glu Asp Lys Ser Lys Lys Lys Gly Gln Glu  
 20 25 30

gaa aaa caa cct aaa aag cag cct aag aag gat gaa gag ggc cag aag 144  
 Glu Lys Gln Pro Lys Lys Gln Pro Lys Lys Asp Glu Glu Gly Gln Lys  
 35 40 45

gaa gaa gat aag cca aga aaa gag ccg gat aaa aaa gag ggg aag aaa 192  
 Glu Glu Asp Lys Pro Arg Lys Glu Pro Asp Lys Lys Glu Gly Lys Lys  
 50 55 60

gaa gtt gaa tca aaa agg aaa aat tta gct aaa aca ggg gtt act tca 240  
 Glu Val Glu Ser Lys Arg Lys Asn Leu Ala Lys Thr Gly Val Thr Ser  
 65 70 75 80

acc tcc gat tct gaa gaa gaa gga gat gat caa gaa ggt gaa aag aag 288  
 Thr Ser Asp Ser Glu Glu Glu Gly Asp Asp Gln Glu Gly Glu Lys Lys  
 85 90 95

aga aaa ggt ggg agg aac ttt cag act gct cac aga agg aat atg ctg 336  
 Arg Lys Gly Gly Arg Asn Phe Gln Thr Ala His Arg Arg Asn Met Leu  
 100 105 110

aaa ggc caa cat gag aaa gaa gca gca gat cga aaa cgc aag caa gag 384  
 Lys Gly Gln His Glu Lys Glu Ala Ala Asp Arg Lys Arg Lys Gln Glu  
 115 120 125

gaa caa atg gaa act gag cag cag aat aaa gat gaa gga aag aag cca 432  
 Glu Gln Met Glu Thr Glu Gln Gln Asn Lys Asp Glu Gly Lys Lys Pro  
 130 135 140

gaa gtt aag aaa gtg gag aag aag cga gaa aca tca atg gat tct cga 480  
 Glu Val Lys Lys Val Glu Lys Lys Arg Glu Thr Ser Met Asp Ser Arg  
 145 150 155 160

|   |      |
|---|------|
| ctt caa agg ata cat gct gag att aaa aat tca ctc aaa att gat aat | 528  |
| Leu Gln Arg Ile His Ala Glu Ile Lys Asn Ser Leu Lys Ile Asp Asn |      |
| 165 170 175   |      |
| ctt gat gtg aac aga tgc att gag gcc ttg gat gaa ctt gct tca ctt | 576  |
| Leu Asp Val Asn Arg Cys Ile Glu Ala Leu Asp Glu Leu Ala Ser Leu |      |
| 180 185 190   |      |
| cag gtc aca atg caa caa gct cag aaa cac aca gag atg att act aca | 624  |
| Gln Val Thr Met Gln Gln Ala Gln Lys His Thr Glu Met Ile Thr Thr |      |
| 195 200 205   |      |
| ctg aaa aaa ata cgg cga ttc aaa gtt agt cag gta atc atg gaa aag | 672  |
| Leu Lys Lys Ile Arg Arg Phe Lys Val Ser Gln Val Ile Met Glu Lys |      |
| 210 215 220   |      |
| tct aca atg ttg tat aac aag ttt aag aac atg ttc ttg gtt ggt gaa | 720  |
| Ser Thr Met Leu Tyr Asn Lys Phe Lys Asn Met Phe Leu Val Gly Glu |      |
| 225 230 235 240   |      |
| gga gat tcc gtg atc acc caa gtg ctg aat aaa tct ctt gct gaa caa | 768  |
| Gly Asp Ser Val Ile Thr Gln Val Leu Asn Lys Ser Leu Ala Glu Gln |      |
| 245 250 255   |      |
| aga cag cat gag gaa gcg aat aaa acc aaa gat caa ggg aag aaa ggg | 816  |
| Arg Gln His Glu Glu Ala Asn Lys Thr Lys Asp Gln Gly Lys Lys Gly |      |
| 260 265 270   |      |
| cca aac aaa aag cta gag aag gaa caa aca ggg tca aag act cta aat | 864  |
| Pro Asn Lys Lys Leu Glu Lys Glu Gln Thr Gly Ser Lys Thr Leu Asn |      |
| 275 280 285   |      |
| gga gga tct gat gct caa gat ggt aat cag cca caa cat aac ggg gag | 912  |
| Gly Gly Ser Asp Ala Gln Asp Gly Asn Gln Pro Gln His Asn Gly Glu |      |
| 290 295 300   |      |
| agc aat gaa gac agc aaa gac aac cat gaa gcc agc acg aag aaa aag | 960  |
| Ser Asn Glu Asp Ser Lys Asp Asn His Glu Ala Ser Thr Lys Lys Lys |      |
| 305 310 315 320   |      |
| cca tcc agt gaa gag aga gag act gaa ata tct ctg aag gat tct aca | 1008 |
| Pro Ser Ser Glu Glu Arg Glu Thr Glu Ile Ser Leu Lys Asp Ser Thr |      |
| 325 330 335   |      |
| cta gat aac   | 1017 |
| Leu Asp Asn   |      |

<210> 8  
 <211> 339  
 <212> PRT  
 <213> Homo Sapiens

&lt;220&gt;

&lt;221&gt; PEPTIDE

&lt;222&gt; (1)... (339)

&lt;400&gt; 8

Lys Pro Arg Gly Arg Pro Lys Met Val Lys Gln Pro Cys Pro Ser Glu  
 1 5 10 15  
 Ser Asp Ile Ile Thr Glu Glu Asp Lys Ser Lys Lys Lys Gly Gln Glu  
 20 25 30  
 Glu Lys Gln Pro Lys Lys Gln Pro Lys Lys Asp Glu Glu Gly Gln Lys  
 35 40 45  
 Glu Glu Asp Lys Pro Arg Lys Glu Pro Asp Lys Lys Glu Gly Lys Lys  
 50 55 60  
 Glu Val Glu Ser Lys Arg Lys Asn Leu Ala Lys Thr Gly Val Thr Ser  
 65 70 75 80  
 Thr Ser Asp Ser Glu Glu Glu Gly Asp Asp Gln Glu Gly Glu Lys Lys  
 85 90 95  
 Arg Lys Gly Gly Arg Asn Phe Gln Thr Ala His Arg Arg Asn Met Leu  
 100 105 110  
 Lys Gly Gln His Glu Lys Glu Ala Asp Arg Lys Arg Lys Gln Glu  
 115 120 125  
 Glu Gln Met Glu Thr Glu Gln Gln Asn Lys Asp Glu Gly Lys Lys Pro  
 130 135 140  
 Glu Val Lys Lys Val Glu Lys Lys Arg Glu Thr Ser Met Asp Ser Arg  
 145 150 155 160  
 Leu Gln Arg Ile His Ala Glu Ile Lys Asn Ser Leu Lys Ile Asp Asn  
 165 170 175  
 Leu Asp Val Asn Arg Cys Ile Glu Ala Leu Asp Glu Leu Ala Ser Leu  
 180 185 190  
 Gln Val Thr Met Gln Gln Ala Gln Lys His Thr Glu Met Ile Thr Thr  
 195 200 205  
 Leu Lys Lys Ile Arg Arg Phe Lys Val Ser Gln Val Ile Met Glu Lys  
 210 215 220  
 Ser Thr Met Leu Tyr Asn Lys Phe Lys Asn Met Phe Leu Val Gly Glu  
 225 230 235 240  
 Gly Asp Ser Val Ile Thr Gln Val Leu Asn Lys Ser Leu Ala Glu Gln  
 245 250 255  
 Arg Gln His Glu Glu Ala Asn Lys Thr Lys Asp Gln Gly Lys Lys Gly  
 260 265 270  
 Pro Asn Lys Lys Leu Glu Lys Glu Gln Thr Gly Ser Lys Thr Leu Asn  
 275 280 285  
 Gly Gly Ser Asp Ala Gln Asp Gly Asn Gln Pro Gln His Asn Gly Glu  
 290 295 300  
 Ser Asn Glu Asp Ser Lys Asp Asn His Glu Ala Ser Thr Lys Lys Lys  
 305 310 315 320  
 Pro Ser Ser Glu Glu Arg Glu Thr Glu Ile Ser Leu Lys Asp Ser Thr  
 325 330 335  
 Leu Asp Asn

&lt;210&gt; 9

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens



<220>  
 <221> PEPTIDE  
 <222> (1)...(13)

<400> 9  
 Phe Ala Lys Met Lys Gly Tyr Pro His Trp Pro Ala Arg  
 1 5 10

<210> 10  
 <211> 15  
 <212> PRT  
 <213> Homo Sapiens

<220>  
 <221> PEPTIDE  
 <222> (1)...(15)

<400> 10  
 Phe Phe Phe Gly Thr His Glu Thr Ala Phe Leu Gly Pro Lys Asp  
 1 5 10 15

<210> 11  
 <211> 9  
 <212> PRT  
 <213> Homo Sapiens

<220>  
 <221> PEPTIDE  
 <222> (1)...(9)

<400> 11  
 Gly Lys Pro Asn Lys Arg Lys Gly Phe  
 1 5

<210> 12  
 <211> 6  
 <212> PRT  
 <213> Homo Sapiens

<220>  
 <221> PEPTIDE  
 <222> (1)...(6)

<400> 12  
 Glu Gly Leu Trp Glu Ile  
 1 5

<210> 13  
 <211> 1586  
 <212> DNA  
 <213> Homo Sapiens

<400> 13  
 atgactcgcg atttcaaacc tggagacctc atcttcgcca agatgaaagg ttatcccat 60  
 tggccagctc gagtagacga agttcctgat ggagctgtaa agccaccac aaacaaacta 120

```

cccattttct tttttggaac tcatgagact gcttttttag gaccaaagga tatatttcct 180
tactcagaaa ataaggaaaa gtatggcaaa ccaaataaaa gaaaagggtt taatgaagggt 240
ttatggggaga tagataacaa tccaaaagtg aaattttcaa gtcaacaggc agcaactaaa 300
caatcaaagt catcatctga tgttgaagtt gaagaaaagg aaactagtgt ttcaaaggaa 360
gataccgacc atgaagaaaa agccagcaat gaggatgtga ctaaagcagt tgacataact 420
actccaaaag ctgccagaag ggggagaaaag agaaaggcag aaaaacaagt agaaactgag 480
gaggcaggag tagtgacaac agcaacagca tctgttaatc taaaagtgag tcctaaaaga 540
ggacgacctg cagctacaga agtcaagatt ccaaaaacca gaggcagacc caaatgggtg 600
aaacagccct gtccttcaga gaggacatc attactgaag aggacaaaag taagaaaaag 660
gggcaagagg aaaaacaacc taaaaagcag cctaagaagg atgaagaggg ccagaaggaa 720
gaagataagc caagaaaaga gccggataaa aaagagggga agaaagaagt tgaatcaaaa 780
aggaaaaatt tagctaaaac aggggttact tcaacctccg attctgaaga agaaggagat 840
gatcaagaag gtgaaaagaa gagaaaaggt gggaggaact ttcagactgc tcacagaagg 900
aatatgctga aaggccaaca tgagaaagaa gcagcagatc gaaaacgcaa gcaagaggaa 960
caaatggaaa ctgagcagca gaataaagat gaaggaaaga agccagaagt taagaaagtg 1020
gagaagaagc gagaaacatc aatggattct cgacttcaaa ggatacatgc tgagattaaa 1080
aattcactca aaattgataa tcttgatgtg aacagatgca ttgaggcctt ggatgaactt 1140
gcttcacttc aggtcacaat gcaacaagct cagaaacaca cagagatgat tactacactg 1200
aaaaaaatc aggcattcaa agttagtcag gtaatcatgg aaaagtctac aatgttgtat 1260
aacaagttta agaacatggt cttggttggt gaaggagatt ccgtgatcac ccaagtgtctg 1320
aataaatctc ttgctgaaca aagacagcat gaggaagcga ataaaaccaa agatcaaggg 1380
aagaaagggc caaacaacaaa gctagagaag gaacaacacag ggtcaaagac tctaaatgga 1440
ggatctgatg ctcaagatgg taatcagcca caacataacg gggagagcaa tgaagacagc 1500
aaagacaacc atgaagccag cacgaagaaa aagccatcca gtgaagagag agagactgaa 1560
atatctctga aggattctac actaga 1586

```

&lt;210&gt; 14

&lt;211&gt; 240

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;400&gt; 14

```

Met Ser Arg Ser Asn Arg Gln Lys Glu Tyr Lys Cys Gly Asp Leu Val
1 5 10 15
Phe Ala Lys Met Lys Gly Tyr Pro His Trp Pro Ala Arg Ile Asp Glu
20 25 30
Met Pro Glu Ala Ala Val Lys Ser Thr Ala Asn Lys Tyr Gln Val Phe
35 40 45
Phe Phe Gly Thr His Glu Thr Ala Phe Leu Gly Pro Lys Asp Leu Phe
50 55 60
Pro Tyr Glu Glu Ser Lys Glu Lys Phe Gly Lys Pro Asn Lys Arg Lys
65 70 75 80
Gly Phe Ser Glu Gly Leu Trp Glu Ile Glu Asn Asn Pro Thr Val Lys
85 90 95
Ala Ser Gly Tyr Gln Ser Ser Gln Lys Lys Ser Cys Val Glu Glu Pro
100 105 110
Glu Pro Glu Pro Glu Ala Ala Glu Gly Asp Gly Asp Lys Lys Gly Asn
115 120 125
Ala Glu Gly Ser Ser Asp Glu Glu Gly Lys Leu Val Ile Asp Glu Pro
130 135 140
Ala Lys Glu Lys Asn Glu Lys Gly Ala Leu Lys Arg Arg Ala Gly Asp
145 150 155 160
Leu Leu Glu Asp Ser Pro Lys Arg Pro Lys Glu Ala Glu Asn Pro Glu
165 170 175
Gly Glu Glu Lys Glu Ala Ala Thr Leu Glu Val Glu Arg Pro Leu Pro

```

[illegible]

```
<210> 15
<211> 237
<212> PRT
<213> Mus Musculus
```

|          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| <400> 15 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Met      | Ser | Arg | Ser | Asn | Arg | Gln | Lys | Glu | Tyr | Lys | Cys | Gly | Asp | Leu | Val |
| 1        |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Phe      | Ala | Lys | Met | Lys | Gly | Tyr | Pro | His | Trp | Pro | Ala | Arg | Ile | Asp | Glu |
|          |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Met      | Pro | Glu | Ala | Ala | Val | Lys | Ser | Thr | Ala | Asn | Lys | Tyr | Gln | Val | Phe |
|          |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Phe      | Phe | Gly | Thr | His | Glu | Thr | Ala | Phe | Leu | Gly | Pro | Lys | Asp | Leu | Phe |
|          | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Pro      | Tyr | Glu | Glu | Ser | Lys | Glu | Lys | Phe | Gly | Lys | Pro | Asn | Lys | Arg | Lys |
| 65       |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |
| Gly      | Phe | Ser | Glu | Gly | Leu | Trp | Glu | Ile | Glu | Asn | Asn | Pro | Thr | Val | Lys |
|          |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Ala      | Ser | Gly | Tyr | Gln | Ser | Ser | Gln | Lys | Lys | Ser | Cys | Ala | Ala | Glu | Pro |
|          |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Glu      | Val | Glu | Pro | Glu | Ala | His | Glu | Gly | Asp | Gly | Asp | Lys | Lys | Gly | Ser |
|          |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
| Ala      | Glu | Gly | Ser | Ser | Asp | Glu | Glu | Gly | Lys | Leu | Val | Ile | Asp | Glu | Pro |
|          | 130 |     |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |
| Ala      | Lys | Glu | Lys | Asn | Glu | Lys | Gly | Thr | Leu | Lys | Arg | Arg | Ala | Gly | Asp |
| 145      |     |     |     | 150 |     |     |     |     |     | 155 |     |     |     |     | 160 |
| Val      | Leu | Glu | Asp | Ser | Pro | Lys | Arg | Pro | Lys | Glu | Ser | Gly | Asp | His | Glu |
|          |     |     |     | 165 |     |     |     |     | 170 |     |     |     |     | 175 |     |
| Glu      | Glu | Asp | Lys | Glu | Ile | Ala | Ala | Leu | Glu | Gly | Glu | Arg | His | Leu | Pro |
|          |     | 180 |     |     |     |     |     | 185 |     |     |     |     | 190 |     |     |
| Val      | Glu | Val | Glu | Lys | Asn | Ser | Thr | Pro | Ser | Glu | Pro | Asp | Ser | Gly | Gln |
|          |     | 195 |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |
| Gly      | Pro | Pro | Ala | Glu | Glu | Glu | Glu | Gly | Glu | Glu | Glu | Ala | Ala | Lys | Glu |
|          | 210 |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |
| Glu      | Ala | Glu | Ala | Pro | Gly | Val | Arg | Asp | His | Glu | Ser | Leu |     |     |     |
| 225      |     |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     |     |

```
<210> 16
<211> 510
<212> PRT
<213> Homo Sapiens
```

<400> 16  
 Lys Glu Leu Glu Arg Leu Ser Pro Glu Glu Ala Ala His Gln Lys Ala  
 1 5 10 15  
 Val Val Glu Arg Leu Leu Gln Glu Asp Pro Trp His Val Ala Lys Leu  
 20 25 30

Val Lys Ser Tyr Leu Gln Gln His Asn Ile Pro Gln Arg Glu Val Val  
 35 40 45  
 Asp Thr Thr Gly Leu Asn Gln Ser His Leu Ser Gln His Leu Asn Lys  
 50 55 60  
 Gly Thr Pro Met Lys Thr Gln Lys Arg Ala Ala Leu Tyr Ala Trp Tyr  
 65 70 75 80  
 Val Gly Lys Gln Arg Glu Ile Ala Arg Gln Phe Thr His Ala Gly His  
 85 90 95  
 Ser Met Ile Thr Asp Asp Met Ser Cys Asp Asp Val Pro Asn Lys Lys  
 100 105 110  
 Met Arg Arg Asn Arg Phe Lys Trp Gly Pro Ala Ser Gln Gln Ile Leu  
 115 120 125  
 Phe Gln Ala Tyr Glu Arg Gln Lys Asn Pro Ser Lys Glu Glu Arg Glu  
 130 135 140  
 Ala Leu Val Glu Glu Cys Asn Arg Ala Glu Cys Leu Gln Arg Gly Val  
 145 150 155 160  
 Ser Pro Ser Gln Ala Gln Gly Leu Gly Ser Asn Leu Val Thr Glu Val  
 165 170 175  
 Arg Val Tyr Asn Trp Phe Ala Asn Ser Gly Lys Glu Glu Ala Phe Arg  
 180 185 190  
 His Lys Leu Ala Met Asp Thr Tyr Asn Gly Gln Gln Ser Ser Ala Gln  
 195 200 205  
 Pro Leu Ser Thr His Asp Leu Pro His Gly Lys Thr Pro Gly Phe Arg  
 210 215 220  
 Tyr Thr Gln Asp Ser Ser Thr Asp Arg Ser Ala Ala Met Ala Asn Ser  
 225 230 235 240  
 Gln Ser Thr Leu Ser Pro Ser Ala Leu Glu Pro Ser His Ile Leu Met  
 245 250 255  
 Asn Ser Asp Ser Lys Met Val Pro Val Ser Gly Gly Ser Leu Pro Pro  
 260 265 270  
 Val Cys Thr Leu Thr Ala Leu His Ser Leu Asp His Ser Gln His Thr  
 275 280 285  
 Leu Gly Gln Thr Gln Asn Leu Ile Met Ala Ser Leu Pro Ser Val Met  
 290 295 300  
 Thr Ile Gly Thr Asp Ser Ala Leu Gly Pro Ala Phe Ser Asn Pro Gly  
 305 310 315 320  
 Ser Ser Thr Leu Val Ile Gly Leu Ala Ser Gln Thr Gln Ser Val Pro  
 325 330 335  
 Val Ile Asn Ser Val Gly Ser Ser Leu Thr Thr Leu Gln Ser Val Gln  
 340 345 350  
 Phe Ser Gln Gln Leu His Pro Ser His Gln Gln Pro Ile Val Gln Gln  
 355 360 365  
 Val Gln Ser His Met Ala Gln Ser Pro Phe Met Ala Thr Met Ala Gln  
 370 375 380  
 Leu Gln Ser Pro His Ala Leu Tyr Ser His Lys Pro Glu Val Ala Gln  
 385 390 395 400  
 Tyr Thr Ser Ala Gly Phe Phe Pro Gln Thr Met Val Ile Thr Asp Thr  
 405 410 415  
 Ser Asn Leu Gly Thr Leu Thr Ser Leu Thr Pro Ser Lys Gln Val Val  
 420 425 430  
 Ser His His Pro Thr Ala His Gly Asp Ser Pro Gly Ser Gln Leu His  
 435 440 445  
 Asn Gln Asp Ser Ser Ile Leu His Leu His Pro Ser His Arg Leu Ser  
 450 455 460  
 Pro Ile Pro Thr Val Ser Ser Ala Ser Leu Ile His Tyr His Asn Ser

465                                      470                                      475                                      480  
 Ser Ser Pro Glu Asn His Ser His Leu Leu Ser Pro Ser His Asn Thr  
    485                                      490                                      495  
 Ile Asp Ser Phe Ile Ser Thr Gln Met Ala Ser Ser Ser Gln  
    500                                      505                                      510

<210> 17  
 <211> 310  
 <212> DNA  
 <213> Homo Sapiens

<220>  
 <221> 5'UTR  
 <222> (1)...(310)

<400> 17  
 gggagccgcg cgggagcagc gcagctacgg cggcggcagc ggcggcgcgg ttgcgattcc 60  
 gagccgttga gacgcctctg cggcagctgg tggcgcaggt ggcttgctg gacgcgggta 120  
 gaggcgaccg gccagcaacc gcagcgtcgg cggccgcggc cccggcagca ggcgcgtcgg 180  
 gacgccccga ggcacccctc cccgccccgg ggccccggtg ctggggccgc gtccgcgcgc 240  
 cgcacccccg cgcgcgcgca tctcctcgcc gcctccccgg cttcggaccc ccggtctcgc 300  
 ccccggaac 310

<210> 18  
 <211> 1461  
 <212> DNA  
 <213> Homo Sapiens

<220>  
 <221> 3'UTR  
 <222> (1)...(1461)

<400> 18  
 ctagggttgac atacctggaa tatagagaac acttgagaag tttgtaatgg ttttcatttg 60  
 aaatagactg ctggaagttt aaatttttat aagcataggt ttgatgttga aaacttgttt 120  
 tgagggagaa aatccctttg ttttaaagta aagtaaacat tatcgctaag tgtaacttgt 180  
 gcagtattaa cagctacatt atacagtaaa tgtgggataa aatccattta gaaaatgtta 240  
 aactgctttt ccagacatgg ttgtagcata ttttcaatta gtgtgtgtat gttaatgtgt 300  
 aattgatagt agaacaaagt tacattttta aaactgctac ttgtataaac ctgacctctt 360  
 ttcccaaata ctgtgggttt tgtgcatagt ttttcaaac cttggattta ccagactgtc 420  
 ttttcaactgt ttgtgggttt tgtagaagt acacattttt atggtagata aaatgttact 480  
 tctatacaag tactcactcc ctttttatca aaagttaatt ttaatctcac agtctacatt 540  
 gtgtacatt atccagcttc tttggaacaa tgtgtgctct gtatggtttt ttttgggtatg 600  
 acaactaatt aagcaactga cattgaactg agaattctac aaactataaa acattaattt 660  
 ttgaaggtaa ttttagttttg tggctgggca ttcagtgaag tcttaggact tctttgcaga 720  
 caactgactg ggtatatata ggaatgaatc tggcttttagg gttaaactcat ttaaggctct 780  
 tttataggca ggcactagta actaaaactg aaaactaagt aagtttattt ttgaggaatg 840  
 ttgttaaaaa tgtcttttagg aagtcactaa aacttaattg gaagaaaaaa tcatgatgct 900  
 tatacaataa atatgaataa atgttatata aggaaactca cctatttgaa atcatggcta 960  
 tattgttttt attttctaga ttccaaaaat acaaacacta gttgttccag cattgtactt 1020  
 tgataagtct gtacattgac gtgtatggac taaatccagg gtaaaatcaa tgttacaaaa 1080  
 ttttaagggtg tggttaactaa aggatagcat ttctaagata ttttgaatat tagggtcatt 1140  
 tggcacttct cagcaagtag gatacttctc atgtttttga aatttatatga atatggaaaa 1200  
 aaatggctta agaccagcgt ctctgtatga cattgtgtgg ttgacctct gagataactg 1260  
 ttttcatcta cagaattgca tttttgcttt taaagaggtc ttataatgga actaggaatc 1320

accgttttga gagaacctgc atatatacca gtcattatct gtttggtcct tatacagttt 1380  
 taacttactt agattttattc tagttaagcc ataagttcaa cgtgtaaaact tgtttttcatt 1440  
 aaagaatttt tctatcaaaa a 1461

<210> 19  
 <211> 31  
 <212> DNA  
 <213> Homo Sapiens

<400> 19  
 ccccgatcc atgactcgcg atttcaaacc t 31

<210> 20  
 <211> 31  
 <212> DNA  
 <213> Homo Sapiens

<400> 20  
 tcttgaattc tgtagctgca ggtcgctctc t 31

<210> 21  
 <211> 2525  
 <212> DNA  
 <213> Homo Sapiens

<300>  
 <308> U94319  
 <309> 1997-04-21

<400> 21  
 agaggacgac ctgcagctac agaagtcaag attccaaaac caagaggcag acccaaaatg 60  
 gtaaaacagc cctgtccttc agagagtgac atcattactg aagaggacaa aagtaagaaa 120  
 aaggggcaag aggaaaaaca acctaaaaag cagcctaaga aggatgaaga gggccagaag 180  
 gaagaagata agccaagaaa agagccggat aaaaaagagg ggaagaaaga agttgaatca 240  
 aaaaggaaaa atttagctaa aacagggggtt acttcacctt ccgattctga agaagaagga 300  
 gatgatcaag aagggtgaaaa gaagagaaaa ggtgggagga actttcagac tgctcacaga 360  
 aggaatatgc tgaaaggcca acatgagaaa gaagcagcag atcgaaaacg caagcaagag 420  
 gaacaaatgg aaactgagca gcagaataaa gatgaaggaa agaagccaga agttaagaaa 480  
 gtggagaaga agcgagaaac atcaatggat tctcgacttc aaaggatata tgctgagatt 540  
 aaaaattcac tcaaaattga taatcttgat gtgaacagat gcattgaggc cttggatgaa 600  
 cttgcttcac ttcagggtcac aatgcaacaa gctcagaaac acacagagat gattactaca 660  
 ctgaaaaaaa tacggcgatt caaagttagt caggtaatca tggaaaagtc tacaatgttg 720  
 ttttaacaagt ttaagaacat gttcttggtt ggtgaaggag attccgtgat cacccaagtg 780  
 ctgaataaat ctcttgctga acaaagacag catgaggaag cgaataaaac caaagatcaa 840  
 gggaagaaag ggccaaacaa aaagctagag aaggaacaaa caggggtcaa gactctaata 900  
 ggaggatctg atgctcaaga tggtaatcag ccacaacata acggggagag caatgaagac 960  
 agcaaagaca accatgaagc cagcacgaag aaaaagccat ccagtgaaga gagagagact 1020  
 gaaatatctc tgaaggattc tacactagat aactaggttg acatacctgg aatatagaga 1080  
 acacttgaga agtttgtaat ggttttcatt tgaaatagac tgctgaaagt tttaaatttt 1140  
 tataagcata ggtttgatgt tgaaaacttg ttttgaggga gaaaatccct ttgttttaaa 1200  
 gtaaagtaaa cattatcgct aagtgtactt gtgcagtatt aacagctaca ttatacagta 1260  
 aatgtgggat ggaatccatt taggaaatgt taaactgctt ttccagacat ggttgtagca 1320  
 tattttcaat tagtgtgtgt atgttaatgt gtaattgata gtagaacaaa gttacatttt 1380  
 taaaactgct acttgataa accttgctc ttttcccaa tactgtgggt tttgtgcata 1440  
 gtttttacia accttggtt taccagactg tcttttctact gtttgtgggt tttgtagaag 1500

```

ttacacattt ttatggtaga taaaatgtta cttctataca agtactcact ccctttttat 1560
caaaaagttaa ttttaatctc acagtctaca ttgtgctaca ttatccagct tctttggaac 1620
aatgtgtgct ctgtatgggt ttttttggtg tgacaactaa ttaagcaact gacattgaac 1680
tgagaattct acaaaactata aaacattaat ttttgaaggt aatttagttt tgtggctggg 1740
cattcagtga agtcttagga cttctttgca gacaactgac tgggtatata taggaatgaa 1800
tctggcttta gggttaaatc atttaagggt cttttatagg caggcactag taactaaaac 1860
tgaaaactaa gtaagtttat ttttgaggaa tgttggtaaa aatgtcttta ggaagtcact 1920
aaaacttaat tggaagaaaa aatcatgatg cttatacaat aaatatgaat aaatgttata 1980
taaggaaact cacctatttg aaatcatggc tatattgttt ttattttcta gattcccaca 2040
aatacacaca ctagtgtgtc cagcattgta ctttgataag tctgtacatt gacgtgtatg 2100
gactaaatcc agggtaaaat caatgttaca aaatttaagg gtatgttaac taaaggatag 2160
catttctaag atattttgaa tattaggggtc atttggcact tctcagcaag taggatactt 2220
ctcatgtttt gaaattatat gaatatggaa aaaaatgggt taagaccagc gtctctgtat 2280
gacattgtgt ggtgacctc tgagataact gttttcatct acagaattgc atttttgctt 2340
ttaaagaggt cttataatgg aactaggaat caccgttttg agaggacctg catatatacc 2400
agtcattatc tgtttggtcc ttatacagtt ttaacttact tagattttatt ctagttaagc 2460
cataagttcc acgtgtaaac ttgttttcat taaagaattt ttctatcaaa aaaaaaaaaa 2520
aaaaa 2525

```

<210> 22  
 <211> 351  
 <212> PRT  
 <213> Homo Sapiens

```

<400> 22
Arg Gly Arg Pro Ala Ala Thr Glu Val Lys Ile Pro Lys Pro Arg Gly
1          5          10          15
Arg Pro Lys Met Val Lys Gln Pro Cys Pro Ser Glu Ser Asp Ile Ile
20          25          30
Thr Glu Glu Asp Lys Ser Lys Lys Lys Gly Gln Glu Glu Lys Gln Pro
35          40          45
Lys Lys Gln Pro Lys Lys Asp Glu Glu Gly Gln Lys Glu Glu Asp Lys
50          55          60
Pro Arg Lys Glu Pro Asp Lys Lys Glu Gly Lys Lys Glu Val Glu Ser
65          70          75          80
Lys Arg Lys Asn Leu Ala Lys Thr Gly Val Thr Ser Pro Ser Asp Ser
85          90          95
Glu Glu Glu Gly Asp Asp Gln Glu Gly Glu Lys Lys Arg Lys Gly Gly
100         105         110
Arg Asn Phe Gln Thr Ala His Arg Arg Asn Met Leu Lys Gly Gln His
115         120         125
Glu Lys Glu Ala Ala Asp Arg Lys Arg Lys Gln Glu Glu Gln Met Glu
130         135         140
Thr Glu Gln Gln Asn Lys Asp Glu Gly Lys Lys Pro Glu Val Lys Lys
145         150         155         160
Val Glu Lys Lys Arg Glu Thr Ser Met Asp Ser Arg Leu Gln Arg Ile
165         170         175
His Ala Glu Ile Lys Asn Ser Leu Lys Ile Asp Asn Leu Asp Val Asn
180         185         190
Arg Cys Ile Glu Ala Leu Asp Glu Leu Ala Ser Leu Gln Val Thr Met
195         200         205
Gln Gln Ala Gln Lys His Thr Glu Met Ile Thr Thr Leu Lys Lys Ile
210         215         220
Arg Arg Phe Lys Val Ser Gln Val Ile Met Glu Lys Ser Thr Met Leu
225         230         235         240

```

Phe Asn Lys Phe Lys Asn Met Phe Leu Val Gly Glu Gly Asp Ser Val  
245 250 255  
Ile Thr Gln Val Leu Asn Lys Ser Leu Ala Glu Gln Arg Gln His Glu  
260 265 270  
Glu Ala Asn Lys Thr Lys Asp Gln Gly Lys Lys Gly Pro Asn Lys Lys  
275 280 285  
Leu Glu Lys Glu Gln Thr Gly Ser Lys Thr Leu Asn Gly Gly Ser Asp  
290 295 300  
Ala Gln Asp Gly Asn Gln Pro Gln His Asn Gly Glu Ser Asn Glu Asp  
305 310 315 320  
Ser Lys Asp Asn His Glu Ala Ser Thr Lys Lys Lys Pro Ser Ser Glu  
325 330 335  
Glu Arg Glu Thr Glu Ile Ser Leu Lys Asp Ser Thr Leu Asp Asn  
340 345 350



# INTERNATIONAL SEARCH REPORT

Application No  
PCT/US 98/09801

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/18 C07K14/475 C12N5/10 G01N33/68 G01N33/53  
A61K38/18

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|----------|---|-----------------------|
| X        | EMHUM2 DATRABASE<br>Accession number U94319<br>Ochs R.L. et al<br>22-APR-1997 (Rel. 51, Last updated,<br>Version )<br>Autoantibodies in atopic dermatitis and<br>interstitial cystitis ; characterization<br>of the major autoantibody/autoantigen<br>system<br>XP002085927 | 1-20,22               |
| X        | see the whole document<br>& TRHUM DATABASE<br>Accession number 000256<br>OCHS R.L. et al.<br>01-JUL-1997 (TREMBLREL. 04, LAST<br>ANNOTATION UPDATE)<br>DFS70 (FRAGMENT) ; HOMO SAPIENS (HUMAN)<br>see the whole document<br>-----<br>-/-                                    | 1-20,22               |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

26 November 1998

Date of mailing of the international search report

09/12/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Gurdjian, D

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 98/09801

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |   |                       |
|--|---|-----------------------|
| Category   | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
| X  | NAKAMURA H ET AL: "Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein."<br>J BIOL CHEM, OCT 7 1994, 269 (40)<br>P25143-9, XP002085924<br>UNITED STATES<br>see the whole document<br>--- | 4-7                   |
| X  | IZUMOTO Y (REPRINT) ET AL:<br>"Hepatoma-derived growth factor belongs to a gene family in mice showing significant homology in the amino terminus"<br>BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 238, 26-32,<br>XP002085925<br>see the whole document<br>---  | 4-7                   |
| A  | WO 94 01124 A (CELTRIX PHARMA)<br>20 January 1994<br>see claims 1-40<br>---   | 23-29,<br>47,48       |
| A  | WO 95 09004 A (ALCON LAB INC) 6 April 1995<br><br>see claims 1-11<br>---  | 23-29,<br>47,48       |
| A  | WO 96 09054 A (PHARMACIA AB ; STJERNSCHANTZ JOHAN (SE); RESUL BAHRAM (SE))<br>28 March 1996<br>see claims 1-7.<br>---   | 23-29,<br>47,48       |
| A  | WO 92 19727 A (NAT INST HEALTH)<br>12 November 1992<br>see abstract; claims 1-6<br>---  | 1-16,22               |
| A  | ALTERIO J ET AL: "Characterization of a bovine acidic FGF cDNA clone and its expression in brain and retina."<br>FEBS LETT, DEC 19 1988, 242 (1) P41-6,<br>XP002085926<br>NETHERLANDS<br>see the whole document<br>---  | 1-16,22               |
| P,X  | EMBL DATABASE<br>Accession number AF063020<br>Singh D.P. ET AL.<br>2-JUL-1998 (Rel. 56, Created)<br>Homo sapiens lens epithelium-derived growth factor mRNA<br>XP002085928<br>see the whole document<br>-----   | 1-16,22               |

1

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/09801

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Please see Further Information sheet enclosed.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/ US 98/09801

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark: Although claims 31-34, 44-46, 49-51, 61-63 and claims 52-60, 64-73, as far as they concern an in vivo method, are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/09801

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s)  | Publication<br>date  |
|---|---------------------|---|--|
| WO 9401124 A                              | 20-01-1994          | AU 4668193 A<br>CA 2138644 A<br>EP 0651650 A<br>JP 8502033 T<br>US 5767079 A  | 31-01-1994<br>20-01-1994<br>10-05-1995<br>05-03-1996<br>16-06-1998 |
| WO 9509004 A                              | 06-04-1995          | AU 7846894 A<br>EP 0670733 A<br>JP 8503969 T<br>US 5696091 A                  | 18-04-1995<br>13-09-1995<br>30-04-1996<br>09-12-1997               |
| WO 9609054 A                              | 28-03-1996          | AU 3581695 A<br>CA 2200481 A<br>EP 0782447 A<br>JP 10505860 T<br>US 5760075 A | 09-04-1996<br>28-03-1996<br>09-07-1997<br>09-06-1998<br>02-06-1998 |
| WO 9219727 A                              | 12-11-1992          | US 5328990 A<br>AU 1990992 A<br>US 5656737 A                                  | 12-07-1994<br>21-12-1992<br>12-08-1997                             |

This Page is inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images  
problems checked, please do not report the  
problems to the IFW Image Problem Mailbox**